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ABSTRACT
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Megan M. Anderson
University of Wisconsin-Milwaukee, 2017
Under the Supervision of Professor Dr. Jennifer Doering
Background: The prevalence of gestational diabetes mellitus (GDM) continues to
increase. Research suggests that adverse maternal and newborn outcomes increase in relation to
the mother’s elevated blood glucose levels. Diabetes researchers discuss that utilizing
information technology for self-management, particularly Internet-based modes of delivery, may
result in individual improvements in diabetes outcomes. Scant research exists on the use of
Internet-based tools such as patient web portals (PWPs) for GDM self-management and
outcomes.
Purpose: The purpose of this study was to examine PWP use in women with GDM.
Specific aims of this study included: 1) compare the characteristics of nonusers and users of a
patient web portal (PWP) for self-management including relationships between characteristics
and PWP use, 2) in users of the PWP, describe the frequency and patterns of PWP use, and 3)
compare glycemic control between PWP users and nonusers.
Methods: A retrospective study was conducted using electronic health record (EHR)
review of PWP users (n=91) and nonusers (n=67) who sought care in a diabetes and pregnancy
clinic for GDM management.
Results: PWP users were more likely to be employed fulltime than nonusers (p= .011).
There were no statistically significant differences between users and nonusers for the other
patient characteristics. Most users accessed the PWP each month in the third trimester but the
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number of days accessed varied greatly. The AVS [24.31 (SD 25.05)] and appointment
reminders [15.44 (SD 17.00)] were accessed most frequently. Glycemic control did not differ
significantly between users and nonusers (F (1.520, 191.474) = 184.428, p=.559).
Discussion: This research provides insight into the patient characteristics of users and
nonusers of a PWP for a non-chronic condition (GDM) and outlines the features of the PWP
used. Patient web portals should be further stringently evaluated for their usability in this
population of patients including facilitators and barriers to its use as well as dosage of utilization.
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Chapter 1
Background/Problem Identification
The prevalence of gestational diabetes mellitus (GDM) in the United States is as high as
9.2% according to a recent analysis performed by the Center for Disease Control and Prevention,
and it has more than doubled since 1990 (DeSisto, Kim, & Sharma, 2014; Gethun, Nath, Ananth,
Chavez, & Smulian, 2008). Research suggests that GDM may be associated with multiple
pregnancies, obesity, sedentary lifestyle, insufficient sleep, and high maternal age at time of
pregnancy (Kim et al., 2010; Qiu, Enquobahrie, Frederick, Abetew, & Williams, 2010).
The 2010 International Association of Diabetes and Pregnancy Study Group’s (IADPSG)
new screening guidelines revised the criteria for diagnosing GDM, to using a single fasting 75
gram 2-hour oral glucose tolerance test (OGTT). GDM rates are rising while the debate
continues on whether evidence supports the IADPSG’s new screening guidelines versus the
traditional two step screen (e.g. a non-fasted one-hour, 50-gram test followed by a 3- hour, 100
gram OGTT). The new guidelines have the potential for the identification of women with GDM
to nearly double (Metzger, 2010).
Gestational diabetes mellitus is unique in the sense that it is a condition that can
adversely affect both the mother and the unborn baby. Newborns of mothers with poorly
controlled GDM have higher rates of macrosomia, birth injuries such as fractures or nerve
damage, and respiratory complications (Alwan, Tuffnell, & West, 2009). Infants born to mothers
with GDM are also at increased risk for obesity and type 2 diabetes during childhood or
adolescence (Ferrara et al., 2004). Mothers with poorly controlled gestational diabetes mellitus
are at increased risk for cesarean delivery, preterm delivery, and preeclampsia (Bellamy, Casas,
Hingorani, & Williams, 2009; Langer, Yogev, Xanakis, & Brustman, 2005). Women with GDM
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are 2 to 3 times more likely to develop GDM with subsequent pregnancies and have a 7 times
greater risk of developing type 2 diabetes later in life (Bellamy et al., 2009). Furthermore, there
is a 2 to 3 times higher morbidity rate for women and their newborns when GDM is not
adequately managed (Langer et al., 2005).
Conversely, when GDM is diagnosed in a timely manner and well managed, the
maternal, fetal, and newborn health risks are reduced (Carolan, Gill, & Steele, 2012). Gestational
diabetes is typically diagnosed between 24 and 28 weeks of pregnancy providing a short time
(roughly 3 months) for these women to learn about their diagnosis and participate in health
management of their diabetes to optimize outcomes and reduce adverse effects. GDM
management plans typically consist of goal-setting for dietary modifications, exercise, and blood
glucose monitoring (Hoffman, Nolan, Wilson, Oats, & Simmons, 1998). Results from the
Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study found that adverse maternal,
fetal, and neonatal outcomes rise in relation to the mother’s elevated glucose levels (Metzger,
Lowe, Dyer,Trimble, Chaovarindr, & Coustan, 2008). Therefore, the goal of treatment is to
maintain blood glucose levels within recommended ranges, which is accomplished through
rigorous self-management of blood glucose testing, exercise, and dietary adjustments (Carolan,
2015; Hoffman et al., 1998). Women who are not able to maintain blood glucose levels within
the target ranges with diet therapy and exercise may need insulin to control their GDM. The goal
of insulin therapy in addition to diet therapy and exercise is to achieve glucose profiles similar to
those of non-diabetic pregnant women (Moore, 2016).
A key component to GDM treatment and self-management is education. Education is
time intensive for the healthcare team. Research suggests that health care information can be
effectively communicated through the use of information technology by providers and nurses
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thus; providing an additional mode of nurse/patient communication for care delivery (Jackson,
Boren, Brancati, Batts-Turner, & Gary, 2006).
People who actively seek to learn about their health and attempt to manage their health
are more likely to participate in healthy behaviors, engage in self-management of their health,
have higher satisfaction, and achieve better health outcomes (Hibbard & Greene, 2013;
Ricciardi, Mostashari, & Murphy et al., 2013). Patient web portals (PWP) are a part of
electronic health records (EHR) that have shown to be a successful tool among a wide range of
patients including women, those with chronic conditions, and potentially those with lower
income (Ancker et al., 2011; Emont, 2011; Kruse, Bolton & Freriks, 2015; Lam et al., 2013;
McMahon et al., 2005). The success of patient portals have gained the attention of the United
States (US) Centers for Medicare and Medicaid Services (CMS) and are now part of the
meaningful use measures for their EHR incentive programs for eligible professionals and
hospitals (CMS, 2016).
Diabetes research suggests that utilizing information technology for care and selfmanagement, particularly Internet-based modes of delivery results in individual improvements in
diabetes clinical outcomes and quality of care (Kwon et al., 2004; McMahon et al., 2005; Meigs
et al., 2003; Quinn et al., 2008). Specifically, studies of individuals with type 1 and type 2
diabetes who use a patient web portal (PWP) experience lower HgbA1c levels and lower blood
pressure over time than individuals not using a PWP (Fonda, McMahon, Gomes, Hickson, &
Conlin, 2009; McMahon et al., 2005; Quinn et al., 2008). While PWPs have been evaluated in
persons with type 1 and type 2 diabetes their usefulness in patients with GDM has not.
Studies related to GDM note the desire for improved access to effective education and
care delivery using a participatory model which includes chat rooms, message boards, and other
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forms of technology (Nolan, McCrone, & Chertok, 2011). Furthermore, a study by Kaptein et al.
(2014) points to the need to provide education and care to this population that minimizes travel
and time commitments. Patient web portals potentially offer an effective care delivery and selfmanagement tool that may minimize travel and time. Only one study exists in the literature on
the use of a PWP for GDM self-management (Carolan, Steele, & Krenzin, 2015).
Identifying the differences between PWP users and nonusers could provide information
to target and support nonusers in becoming more active in their diabetes self-management.
Variations exist within the literature on definitions and categories of users and nonusers of PWPs
(Ronda, Dijkhorst-Oei, & Rutten, 2015; Sarkar et al., 2011; Weingart, Rind, Tofias, & Sands,
2006; Yamin et al., 2011). For the purposes of this study nonusers will apply to subjects who log
in only once. Users will be classified as either short-term users or persistent users. Short-term
users are women who log in only during the first month after enrollment only. Persistent users
are those who login throughout the third trimester.
In addition, the results of this study could assist organizations with future updates and
revisions to PWPs for GDM management. Effective GDM self-management interventions have
the potential to reduce adverse outcomes for mothers and babies during pregnancy and later in
life. Patient web portals also have the potential to address some of the barriers to GDM selfmanagement as identified by patients related to travel and time and may decrease health care
costs. Keeping in line with Roger’s Diffusion of Innovation Theory, this research can contribute
to the body of knowledge related to early adopters of PWP use and the laggards or non-adopters
so future modifications can be tailored to meet the needs across all levels of adopters (Sahin,
2006).
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Purpose
The purpose of this study was to examine patient web portal (PWP) use in women with
gestational diabetes mellitus (GDM).
Specific Aims
In women with gestational diabetes:
Aim 1: Compare the characteristics of nonusers and users of a patient web portal (PWP) for selfmanagement including relationships between characteristics and PWP use/nonuse.
Aim 2: In users of the PWP, describe the frequency and patterns of PWP use.
Aim 3. Compare glycemic control between PWP users and nonusers.
Theoretical Framework
The Individual and Family Self-Management Theory (IFSMT) by Ryan and Sawin
(2009) was the theoretical foundation of this study. This theory was chosen for several reasons.
The IFSMT suggests applicability beyond chronic conditions and has been utilized in studies on
health promotion and prevention including osteoporosis prevention and postpartum fatigue
(Doering, 2013; Ryan & Sawin, 2009). Furthermore, the theory is comprehensive and maps well
to the variables being studied. The major components of the IFSMT focus on risk and protective
factors, which align with the patient characteristics of this study as well as the condition
complexity. Likewise, the patient web portal (PWP) applies to the process domain of the
IFSMT. Finally, glycemic control relates to the IFSMT as an outcome.
It should be noted that the intent of this study was not to examine the process of selfmanagement rather to determine the patient characteristics (context) of users and nonusers of a
PWP for gestational diabetes mellitus (GDM) self-management. The study explored the
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frequency and patterns of PWP use over the last trimester of pregnancy. Specific features of the
PWP that were measured included flowsheets, lab results, medication refills, secure messaging,
appointment reminders, and patient instructions all of which relate to the process domain of the
IFSMT. Finally, the relationship between PWP use and glycemic control, an outcome, in the
IFSMT, was measured by percentage of blood glucose levels within target range. Figure 1
outlines the relationship of this study’s variables to the IFSMT. The model in figure 2, which
guides the study, includes three major dimensions based on the IFSMT model: Content, Process
and Outcome. The variables for this study are organized into one of these three categories.
Context
According to the IFSMT (Ryan & Sawin, 2009), the context dimension is defined by risk
and protective factors including condition-specific factors, physical and social environments, and
individual and family characteristics. Condition specific factors are structural, functional, or
physiological characteristics of the condition or treatment and may include complexity of the
condition.
Condition specific factors. Condition specific factors in this study were type of GDM
(diet controlled or insulin), number of pregnancies with GDM, and BMI. The physical and
social environment of the context dimension pertains to the physical and social factors that are
barriers or facilitators to self-management. Examples of these factors, as outlined by Ryan and
Sawin (2009), are access to healthcare, culture, and social capital. Race, ethnicity, marital status,
employment, and health insurance were patient characteristics examined in this study that fit into
the physical and social environment construct. The third and final construct of the context
dimension are the individual and family characteristics. These are characteristics of the
individual or family that could promote or inhibit self- management. Age is included as a
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variable in this construct. Table 1 provides a visual of the variables for the study as they relate to
the constructs and concepts of the IFSMT.
Process
The process domain of the IFSMT encompasses the Integrated Theory of Health
Behavior Change (ITHBC) model and includes knowledge and beliefs, self-regulation skills and
abilities, and social facilitation (Ryan & Sawin, 2009). First, knowledge consists of factual
information related to the specific condition and beliefs refer to the personal perceptions about
the health condition or health behavior. Secondly, self-regulation is used to alter health behavior
and includes goal setting, self-monitoring, decision-making, and management of responses
associated with health behavior change. Self-regulation is defined as a process people use to
incorporate a behavior change into their routine. Finally, social facilitation incorporates social
support, social influence, and collaboration between individuals, health care providers, and
families (Ryan and Sawin).
Application of IFSMT to this study. The patient web portal (PWP) in this study
functions as the intervention, which may or may not influence the process dimension of the
IFSMT. A PWP provides access to parts of the electronic health record (EHR). It is hypothesized
that users of the patient portal will experience better glycemic control as measured by a higher
percentage of blood glucose numbers within target range. Patient portals vary in their
functionality but according to the National Learning Consortium and HealthIT.gov (2013),
patient portals typically allow patients to check lab and test results, review health information,
communicate to their health care team, access educational resources, request medication refills,
issue appointment reminders, and handle other tasks such as entering in and monitoring blood
sugar values.
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The PWP in this study has the features listed above and are incorporated into Table 2 to
outline its relationship to the process concepts of the IFSMT. For example, self-monitoring was
measured through frequency of entering and reviewing blood sugars in the blood sugar log,
reviewing lab results, and engaging in behavior to request medication refills using the PWP. The
medication refills could also apply to decision-making. Social support was measured through the
frequency of email communication to the healthcare team using the PWP. Finally, knowledge
was measured through review of educational information on the PWP from the after visit
summaries and flow sheets.
Outcomes
The IFSMT (Ryan & Sawin, 2009) defined outcomes as proximal or distal. The proximal
outcome is engagement in self-management behaviors to manage a condition or symptoms and
pharmacological therapies. Distal outcomes include health status as defined by prevention,
attenuation, stabilization, or worsening of a condition; quality of life; and direct and indirect
costs.
Outcomes of this study. Proximal outcomes were not measured in this study because of
the retrospective nature of the study and the inability to measure the full conceptual definition of
PWP use which includes frequency and time spent in each feature of the PWP. Future research
could incorporate the full conceptual definition of PWP use and potentially measure it as a selfmanagement behavior. The distal outcome variable in this study was glycemic control as
measured by percentage of blood glucose levels within target range. This is an indicator of
health status and determines stabilization of worsening of GDM.
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Conceptual and Operational Definitions
This section provides conceptual and operational definitions relevant to this study.
Gestational Diabetes. Gestational diabetes (GDM) was defined as glucose or
carbohydrate intolerance with onset or first diagnosis during the pregnancy (Carolan, Steele, &
Margetts, 2010; Hui, Sevenhuysen, Harvey, & Salamon, 2014 ). Women who develop type 1
diabetes or who have undiagnosed type 2 diabetes that is verified during pregnancy are
diagnosed with GDM (Nolan et al., 2011). It is a transient condition that can have serious
adverse outcomes for mother and baby (Carolan, Steele, & Margetts, 2010).
Glycemic control. Target blood glucose levels were measured using the percentage of
blood sugars reported each month within target range per subject. Target blood glucose levels
were identified as less than 125 mg/dL for fasting and two hours post-meal (Moore, 2016).
Self-management. Self-management is a dynamic phenomenon consisting of context,
process, and outcomes (Ryan & Sawin, 2009). Individual and family self-management includes
the integration of health-related behaviors into a person and/or family’s daily functioning (Ryan
& Sawin, 2009).
Electronic Health Record (EHR). According to the National Alliance for Health
Information Technology (2008) an EHR is an electronic health-related record on an individual
that meets nationally established interoperability standards and that can be created and managed
by staff across more than one healthcare organization. The Healthcare Information and
Management Systems Society (HIMSS) adds that the EHR is a longitudinal electronic record of
patient’s health information gathered from sources such as office visits, hospital encounters,
problem lists, medications, and allergies (HIMSS, 2016). Most EHRs today include patient
demographics, financial information, lab and diagnostic results, medications, allergies, problem
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lists, and clinical documentation (Seckman, 2014). Standards for EHRs were first developed in
2003 by the EHR Collaborative, under the direction of the U.S. Department of Health and
Human Services (Seckman, 2014)
Patient web portal (PWP). An electronic personal health record that directly links to an
EHR is referred to as a patient web portal (Irizarry, DeVito-Dabbs, & Curran, 2015). The
operational definition of the PWP was the study organization’s PWP, Epic MyChart. MyChart
acts as the point of entry for all features of the PWP at this health care institution. More
information on the functionality of MyChart is discussed in Chapter 3.
Patient web portal use. Patient web portal (PWP) use is not clearly defined in the
literature. Some define it as the amount of time spent in the PWP and the frequency of use or
log-in (Fonda et al., 2009). Others take a more comprehensive approach capturing frequency,
consistency, and duration in their definition of PWP use (Jones, Weiner, Shah, & Stewart, 2015).
The operational definition for pattern of use in this study included frequency and consistency.
Duration was unable to be captured in this study and is noted as a limitation. Frequency was the
utilization of PWP features from first appointment in the diabetes in pregnancy clinic to the time
of delivery. It includes the PWP features accessed and the number of hits on each feature over
the study period. Consistency captures the distribution of PWP use over the study period and was
measured in hit days and hit months. Hit day was any day that the patient accessed the PWP in
the third trimester regardless of the number of times accessed that day or features accessed. Hit
month captured any individual month where the patient accessed any feature of the PWP at least
once.
Patient portal users and nonusers. For the purposes of this study nonusers applied to
subjects who logged in only once. Short-term users were women who stopped logging in after
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the first month of enrollment. Persistent users were users that logged in throughout the third
trimester.
Assumptions
1) PWP use reflects an aspect of self-management (Ryan & Sawin, 2009).
2) PWP users have access to a computer and the technical skills to adequately navigate
the PWP.
3) PWP users enter accurate information into the PWP and interpret PWP information
accurately.
Significance
Practice
Nurses represent one of the largest groups of EHR users therefore; their perspective is
vital to current and future technology success (IOM, 2010; Seckman, 2014). Provider and
clinician endorsement and continued use of PWPs are key factors in a patient’s decision to use a
PWP (Logue & Effken, 2012; Wald, Businger, Gandhi et al., 2010). Knowledge of PWPs and
support of its use by nursing is crucial to the sustainability of this technology since nurses often
are a key source of patient portal activation.
This study contributes to the knowledge of nursing practice as it relates to PWPs by
describing the patient characteristics of users versus nonusers of this technology for GDM selfmanagement. This has the potential to better inform nursing on the similarities and differences
of users and nonusers of PWPs so future modifications to PWPs can occur to either engage the
nonusers or tailor patient education to meet the needs of these patients. This study also reveals
the frequency by which specific features of the PWP were accessed and the patterns of use. This
could prove valuable in providing insight on the key elements of PWPs for self-management.
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This and future studies could determine if there are certain features of a PWP that should be
included in all PWPs in order to work towards determining national standards for PWPs or if
variations should exist to meet the needs of specific populations and conditions.
PWPs are a form of technology that applies to nursing informatics. Nursing informatics is
identified as and has been recognized as a specialty by the American Nursing Association (ANA)
since 2001 (ANA, 2001). Nurse informaticists have the ability to guide PWP engagement
through their design and evaluation, determining what is relevant and user-friendly for portal
users. This research can add to the nursing body of knowledge as it pertains to GDM PWP use.
Theory
This study contributes to theory by utilizing and building upon concepts within Ryan and
Sawin’s IFSMT (2009). While the tenets of the IFSMT are not tested, the variables of this study
represent the context, process, and outcomes domains of the Ryan and Sawin (2009) theory and
this theory guided this study. This study extends the use of the IFSMT theory beyond chronic
conditions into a more acute realm that is unique to pregnancy. Furthermore, it tests the
utilization of a technology tool to aid in self-management. While this study does not determine
if there is a direct correlation between PWP use/engagement and improved glycemic control, it
provides some insight into the patient characteristics of PWP users and nonusers and guides
future research that can further explore this relationship. This could subsequently inform future
research about whether PWP use contributes to self-management.
Research
Meaningful Use, EHRs, and PWPs continue to evolve. The HITECH Act of 2009 and
Meaningful Use incentives have accelerated EHR adoption and they have been the major drivers
for PWP adoption (Gibson, 2014; Irizarry et al., 2015). It is clear that PWP use will continue to

12

be an integral part of the EHR and a means to meet Meaningful Use incentives in the foreseeable
future. What is less clear is the population who will most likely benefit from these portals.
Some research has been conducted on the positive impact of patient portals relative to chronic
disease management such as cardiac disease or diabetes (McMahon et al., 2005; Quinn et al.,
2008; & Fonda et al., 2009). There has been little research on more acute conditions or
preventative management of health.
This research aims to provide insight into the patient characteristics of users and nonusers
of a PWP for GDM self-management and outline the features of the PWP used and patterns of
use. This research contributes to the increasing body of knowledge related to PWP use for a
unique population that is non-chronic care related.
Policy
This study has the potential to influence policy on several levels. At a local level it may
influence policy at this health care organization. At a broader level, this study may contribute to
the body of knowledge related to Meaningful Use. Stage 3 of the CMS EHR incentive program
for Meaningful Use is scheduled to begin in 2017 and focuses on outcomes. The third stage is the
use of EHR data to improve health outcomes, quality, safety, efficiency, and population health at
the national level. The EHR will likely focus on self-management and shared management of
health care including increased use of PWPs (Gibson, 2014; HealthIT, 2013).
There are several Meaningful Use measures that directly relate to the functionality of a
PWP including (1) secure messaging, (2), clinical summary after each visit, (3) patient specific
education, (4) patient reminders, (5) access to personal health record information, and (6)
medication reconciliation (Ahren, Woods, Lightowler, Finley, & Houston, 2011; Irizarry et al.,
2015). However, policy makers have yet to define the minimal criteria of a PWP and the
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principles for an ideal PWP as they have for an EHR. This clarity will be necessary for future
research and advancement of this technology.
This study addresses the specific patient characteristics of users and nonusers of a PWP
for GDM self-management. If an expectation of Meaningful Use is to engage 5% of patients in
the use of PWPs, it is essential that we understand the patient characteristics of users and
nonusers (Irizarry et al., 2015). Understanding the differences between users and nonusers
provides an avenue for future research on how to better tailor PWPs to convert nonusers to users
before health policy dictates a certain practice. Finally, the research findings may point to
patient characteristics such as insurance type, co-morbidities, or type of GDM that should be
understood before financial incentives or penalties are instituted through Meaningful Use for this
population.
Chapter Summary
This chapter proposes a study to fill a gap in the literature on the effective GDM
management and e-strategies to promote GDM self-management using PWPs. Studies exist
demonstrating a relationship between the use of PWPs and improvements in hemoglobin A1c
(HgA1c) in type 1 and type 2 diabetes however; only one study exists for GDM (Carolan, Steele,
& Krenzin, 2015; McMahon et al., 2005; Quinn et al., 2008).
The study purpose and research questions were outlined in this chapter. The theoretical
framework for the study was explained along with rationale and illustration of the link between
the study variables and the IFSMT. In addition, study concepts were defined and assumptions
discussed.

Finally, the significance to nursing practice, theory, research, and policy was

explained and expected limitations were discussed.
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Chapter 2
Review of Literature
The layout of this chapter is structured to provide the reader with an in depth look at the
literature on gestational diabetes, self-management, and patient web portals. The chapter begins
with an overview of GDM including pathophysiology, diagnosis and management, and maternal,
fetal, and newborn effects. Next, literature is reviewed on self-management in general and then
more specifically related to GDM self-management. The final section of this chapter discusses
EHR technology, specifically the use of PWPs, their functionality, their role in self-management
with other conditions, and the overall proposal to study this technology for GDM selfmanagement.
Information in this literature comes from electronic searches of computerized databases,
journals, and texts. EBSCOhost Research Database, PubMed, Google Scholar, The Cumulative
Index to Nursing and Allied Health Literature (CINAHL), and Cochrane Database of Systematic
Reviews were the databases used for this literature review. Other non-peer reviewed
publications such as HealthIt.gov and Health Information Management Systems Society
(HIMSS) were used for context and specific examples relative to PWPs.
The following search terms were employed to capture the literature: “patient web
portals”; “e-health and gestational diabetes”; “patient web portals and diabetes”; “gestational
diabetes self-management”; and “self-management”. Bibliographies and literature reviews from
identified articles were used to identify additional studies. All publications were published in
English. The publications ranged from 1976 through 2016. The earlier publications were used in
reference to the physiology and diagnosis of GDM while more recent literature was referenced in
terms of PWPs due to the rapidly evolving technology.
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GDM
Gestational diabetes mellitus (GDM) is the most common medical complication in
pregnancy (Carr & Gabbe, 1998). The prevalence of GDM in the United States is as high as 9.2
percent according to a recent analysis performed by the Center for Disease Control and
Prevention (DeSisto, Kim, & Sharma, 2014) and is projected to increase in the future. GDM is a
result of insulin resistance and impairment of insulin secretion (American Diabetes Association
[ADA], 2016). The identification and treatment of women with GDM is important to not only
prevent perinatal morbidity but also improve long-term outcomes for mothers and their children.
Pathophysiology
There are many metabolic changes that occur in pregnancy to support the growing fetus.
For example, early in pregnancy, maternal estrogen and progesterone increase, which result in
pancreatic ß-cell hyperplasia and increased insulin release (Kuhl & Holst, 1976). As pregnancy
progresses, increased levels of progesterone, estrogen, and other hormones lead to insulin
resistance in peripheral tissues, which causes the pancreas to release more insulin to respond to
the insulin resistance (Carr & Gabbe, 1998). Patients with normal pancreatic function are able to
meet the increased demands however; patients with altered pancreatic function have difficulty
increasing insulin secretion and therefore produce inadequate levels of insulin. GDM occurs
when there is delayed or insufficient insulin secretion in the presence of increasing peripheral
resistance (ADA, 2016). Cortisol and progesterone have their highest potency and peak effect
between 26 and 32 weeks gestation, which is important in regard to GDM screening timelines
(Carr & Gabbe, 1998).
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Diagnosis
In 1997, an Expert Committee on the Diagnosis and Classification of Diabetes Mellitus,
stated that universal screening may not be needed in women who meet all of the following
criteria: 1) <25 years of age, 2) normal body weight, 3) no first-degree relatives with diabetes
mellitus, 4) not African American, Native American, Asian, or Hispanic (ADA, 1997). In 2013,
the American College of Obstetricians and Gynecologists (ACOG) recommended that all
pregnant patients be screened for GDM based on risk factor identification or administration of 50
gram oral glucose challenge test (OGCT). Other organizations feel that screening by risk factors
is inadequate, since almost half of all patients with GDM have no identifiable risk factors
(Coustan, 1995). Proponents of universal screening for GDM stress that pregnancy is an
opportune time to diagnosis this disease that has both short and long-term effects on mothers and
babies (Carr & Gabbe, 1998). The setting for this study performs universal screening.
Screening methods. There are two methods of screening for GDM. In the 2-step
approach, the 50-gram OGCT is performed between 24 and 28 weeks of gestation in a nonfasting state (U.S. Preventive Services Taskforce, 2015). If the screening threshold is met or
exceeded, patients receive the oral glucose tolerance test (OGTT) (ACOG, 2004). A threshold of
140 mg/dl identifies roughly 90 percent of GDM cases with 15 percent of pregnant patients
meeting criteria to take the 3-hour OGTT (ACOG, 2004). During the OGTT, a fasting glucose
level is obtained. Then the patient is given a 100 gram glucose load and glucose levels are
evaluated after 1, 2, and 3 hours. GDM is diagnosed when 2 or more glucose values fall at or
above the specified glucose thresholds.
When the results of the 1 hour, 50 gram glucose screen results are >185 or a fasting
glucose is >126, the patient does not need to proceed with the 3-hour OGTTA due to the risk to
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produce hyperglycemia (Landy, Gomez, & O’Sullivan, 1996). In these instances, the diagnosis
of GDM can be assumed and treatment should begin.
The 3-hour OGTT should begin after an overnight fast for at least 8 hours, following at
least 3 days of unrestricted diet (>150 g carbohydrate) and usual physical activity (Carr &
Gabbe, 1998). After the 100 gram glucose load is delivered, venous plasma glucose is measured
at fasting and at 1, 2, and 3 hours. ACOG recommends that two or more of the National Diabetes
Data Group (NDDG) values be met or exceeded to make the diagnosis of GDM (ACOG, 2004).
Alternatively, a one time, 75-g glucose load can be administered after fasting and plasma
glucose levels are evaluated after 1 and 2 hours (ADA, 2016). Gestational diabetes is diagnosed
if 1 glucose value falls at or above the specified glucose threshold (U.S Preventative Services
Taskforce, 2015). The 1 step approach has the potential for the identification of women with
GDM to nearly double (Metzger, 2010). The 2-step approach to screening is used at this study
setting.
Other considerations. Patients with certain factors, such as a history of a prior
macrosomic fetus, family history of diabetes, or chronic steroid use, may benefit from earlier
testing, at or before 20 weeks gestation (Gabbe, 1993). Testing can be repeated later in the
pregnancy around 32 to 34 weeks with an initial negative result. A study by Javanovic and
Peterson (1985) found GDM detection increased by about 50 percent by repeating the test at 33
to 36 weeks gestation in high-risk women who were obese, age >33 years, or a positive 1-hour
screen followed by a negative OGTT.
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Maternal effects
Pregnancy/birth complications. Mothers with poorly controlled gestational diabetes
mellitus are at increased risk for many complications during pregnancy and later in life. Study
results have found that women with poorly controlled GDM have increased incidence of
cesarean delivery, preterm delivery, and preeclampsia (Bellamy et al.,2009; Langer et al., 2005;
Yogev, Xenakis, and Langer, 2004). A prospective cohort study conducted by Sermer and
associates (1995) evaluated maternal and fetal outcomes with increasing carbohydrate
intolerance and found associations between glucose intolerance and increased incidence of
preeclampsia, cesarean delivery, and maternal length of hospitalization (P<0.05). In addition, a
key research study of over 25,000 women called the Hyperglycemia and Adverse Pregnancy
(HAPO) study found associations between elevated fasting plasma glucose and increased
primary cesarean section delivery and preeclampsia (P<0.05, OR primary cesarean delivery
=1.11, OR preeclampsia= 1.21) (HAPO, 2008).
Type 2 diabetes. Women with GDM are 2-3 times more likely to develop GDM with
subsequent pregnancies and have a 7 times greater risk of developing type 2 diabetes later in life
(Bellamy et al., 2009). Coustan (1993) studied former GDM women and found diabetes or
impaired glucose tolerance (IGT) in 6 percent of those tested at 0–2 years, 13 percent at 3–4
years, 15 percent at 5–6 years, and 30 percent at 7–10 years postpartum (P<0.001). A study by
Metzger and associates (1985) report a prevalence of 38 percent up to one year postpartum. A
systematic review of 28 studies by Kim, Newton, and Knopp (2002) concluded that most women
progressed to diabetes at a similar rate in the first five year post pregnancy and then leveled off
by 10 years. However, there remains some controversy on the overall risk, due to a large
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Canadian study of more than 25,000 women that reported only a small increased risk of Type 2
diabetes to previous GDM women later in life (HAPO, 2008).
Other complications. The implications of GDM are significant, since women with prior
GDM are at greater risk for developing hypertension, hyperlipidemia, and mortality (O’Sullivan,
1984). Women with GDM are also predisposed to later cardiovascular disease (CVD) ( Reece,
2010). Carr et al., (2006) also compared women with and without a history of GDM and found
that those with prior GDM were more likely to have CVD risk factors including metabolic
syndrome (86.6 vs. 73.5%; P < 0.001) and Type 2 diabetes (93.4 vs. 63.3%; P < 0.001). They
also experienced more CVD events at a younger age (15.5 vs. 12.4%; adjusted odds ratio 1.85
[95% CI 1.21-2.82]; P = 0.005) (Carr et al. 2006).
Fetal/Newborn effects
Anomalies. Infants of mothers with GDM are not at increased risk for congenital
anomalies unless the woman had pre-existing diabetes mellitus and suboptimal glycemic control
before conception (Carr & Gabbe, 1998). In these cases, the anomaly rate has been reported to be
as high as 18% primarily involving the cardiovascular and central nervous system of the fetus
(Becerra, Khoury, Cordero, and Erickson, 1990). Neural tube defects, genitourinary,
gastrointestinal, and skeletal anomalies are also more common in diabetic pregnancies (Moore,
2016). Fortunately, clinical trials of intensive metabolic programs have reduced anomaly rates to
those similar to the nondiabetic women when strict pre-conceptional glycemic control is evident
(Dunne, Brydon, Smith, & Gee, 2003).
Miscarriage. It is also important to note that data suggests a strong association between
the degree of glycemic control before pregnancy and the miscarriage rate. Poor glycemic control
has been shown to double to quadruple the miscarriage rate in women with diabetes (O’Sullivan,
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Charles, Mahan, & Dandrow, 1973; Pettitt, Knowler, Baird, & Bennett, 1980). Additionally,
women with long-standing (>10 years) and poorly controlled diabetes (glycohemoglobin
exceeding 11%) have been shown to have a miscarriage rate of up to 44% (Moore, 2016).
Macrosomia. Newborns of mothers with poorly controlled GDM have higher rates of
macrosomia and birth injuries such as fractures or nerve damage (Alwan, Tuffnell, & West,
2009). Macrosomia complicates about 20 percent of GDM pregnancies and is defined as fetal
weight >90th percentile for gestational age or >4,000 g (Kc, Shakya, & Zhang, 2015). Maternal
hyperglycemia leads to fetal hyperglycemia and fetal hyperinsulinemia, which results in excess
fetal growth. Macrosomic fetuses display a distinct growth pattern with overgrowth occurring in
the abdominal and intrascapular areas (McFarland, Trylovich, & Langer, 1998). The increased
growth in the shoulder region and not the head puts the fetus at risk for shoulder dystocia during
delivery (Kc et al., 2015).
Shoulder dystocia is increased two- to six-fold in fetuses of GDM mothers and even
further increased in newborns with fetal weight greater than 4000 grams (Moore, 2016). A
brachial plexus injury is a serious complication associated with shoulder dystocia and involves
the loss of movement or weakness of an arm from the stretching and pulling of the shoulders
during vaginal delivery (Benedetti, 1991). Most brachial plexus injuries (80–90 percent) will
resolve in the first year however; between 0.2 percent and 2 percent will result in permanent
injury (Blank & Grave, 1992).
Obesity. Many studies highlight the increased risk of obesity in children born to mothers
with GDM. This generational cycle of obesity further perpetuates the risk and incidence of
future pregnancies with GDM. Children who were born to mothers with GDM have double the
rates of obesity compared to children born to nondiabetic mothers (Plagemann, Harder,
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Kohlhoff, Rohde, & Dorner, 1997; Silverman, Metzger, Cho, & Loeb, 1995; Vohr & Boney,
2008). Pettitt and associates studied the children of diabetic Pima Indians from 5 to 19 years of
age and found a significantly higher body weight as compared to control subjects (Pettitt et al.,
1987).
Type 2 diabetes. Children who were born to women with GDM or pregestational
diabetes had 13 times the incidence of impaired glucose intolerance than children born to
nondiabetic mother (Silverman et al., 1995). Between the ages of 10-16 years, McKinney and
associates found, children of a diabetic pregnancy had a 19.3% rate of impaired glucose intolerance
(McKinney, Parslow, Gurney, Law, Bodansky, & Williams, 1999). Fetuses that were born large for

gestational age seem to be at the greatest risk (Eriksson, Forsen, Osmond, & Barker, 2003).
Other complications. There are several other complications that are common among
newborns born to GDM mothers including hypoglycemia, respiratory distress, and
neurodevelopmental changes (Ferrara, 2004). Neonatal hypoglycemia occurs in roughly 50
percent of macrosomic infants. Control of maternal diabetes during the latter half of pregnancy
and during labor and delivery influences the occurrence of neonatal hypoglycemia (U.S.
Preventative Services Taskforce, 2015). In addition, babies born to women with GDM have a
higher incidence of respiratory distress syndrome (DeLuca et al., 2009). Although the reason is
not completely understood, there is evidence that hyperglycemia delays fetal lung maturity thus,
periods of poorly controlled diabetes could delay fetal lung maturity in fetuses born to mothers
with GDM (DeLuca et al., 2009). Infants born to mothers with GDM are also at increased risk
for long-term neurodevelopmental changes (Ferrara et al., 2004). A study by Rizzo and
associates of 196 pregnant women and their singleton children concluded that children had
poorer performance of psychomotor development at 6 and 9 years of age if their mother had
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GDM or pregestational diabetes during pregnancy (P<0.001)(Rizzo, Dooley, Metzger, Cho,
Ogata, & Silverman, 1995).
Clearly, the detection and appropriate management of GDM provides the opportunity to
prevent adverse outcomes for both mothers and their children.
Management
After the diagnosis of GDM is established, treatment is focused on diet/nutrition,
exercise, and glucose monitoring (ADA, 2016).
Nutritional therapy. Diet or nutrition therapy is an important component of GDM
management that often includes nutritional counseling and a personalized nutrition plan with the
goal of achieving normoglycemia and preventing ketosis (ACOG, 2013). The goal of dietary
therapy is to avoid large meals and foods with a lot of simple carbohydrates by dividing meals
into a total of 6 feedings per day, typically with 3 meals and 3 snacks to limit the amount of
glucose circulating in the bloodstream at any given time (Moore, 2016). A study by Gunderson
reviewed intensive nutritional therapy, and emphasized limiting total carbohydrates and
distributing carbohydrates throughout the day via several meals and snacks in order to maintain
normal blood glucose levels (Gunderson, 1997). This is particularly important in pregnancy due
to the continuous fetal draw of glucose from the mother so hypoglycemia can be avoided (ADA,
2008). A minimum of 175 grams of carbohydrate/day should be given and may be increased or
adjusted based on hunger, plasma glucose levels, and ketone levels (Institute of Medicine [IOM],
2002).
The American Diabetes Association recommends that carbohydrates should be no more
than 50 percent of the women’s diet, with fats and protein accounting for the rest (ADA, 2013).
However, Meltzer and colleagues noted that a carbohydrate restriction to 35 to 40 percent of the
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diet decreased maternal glucose levels and improved maternal and fetal outcomes (Meltzer,
Snyder, Penrod, Nudi, & Morin, 2010). The ADA also notes that moderate caloric restriction of
up to 30 percent of energy needs in obese women with GDM may reduce weight gain and
improve glycemic control without ketonemia (ADA, 2008).
Exercise. Exercise has been suggested as an adjuvant therapy in GDM, since exercise has
shown to improve glycemic control in patients with GDM (Bung, Artal, Khodiguin, & Kjos,
1991). Additional studies support the benefits of exercise on glycemic control. A study by
Jovanovic-Peterson and associates compared 50 women with GDM who were assigned to a
dietary treatment with those assigned to diet plus exercise treatment. The study results suggest
significantly lower fasting blood glucose levels in the diet plus exercise group than diet alone
(Jovanovic-Peterson & Peterson, 1990). A meta-analysis of exercise and pregnancy studies
conducted by Lokey and associates concluded that pregnant women can exercise up to 3 times
per week for roughly 40 minutes with no harm to either herself or the fetus (P=.20) (Lokey, Tran,
Wells, Myers, & Tran, 1991).
Glucose monitoring. Hemoglobin A1c (HbA1c) has been an accepted marker of
glycemic control since the mid-1970s and is clinically used to assess glycemic control in people
with diabetes (Saudek & Brick, 2009). In pregnancy, however, A1c may not be the most reliable
measure of glycemic control due to normal physiological increases in red blood cell turnover,
resulting in reduced A1c levels (Nielsen et al., 2004). Furthermore, A1C is an integrated measure
of glucose and may not fully detect postprandial hyperglycemia, which drives macrosomia
(Nielson et al., 2004). As a result, blood glucose self-monitoring and targets are the primary
measures of glycemic control in women with GDM. It is also the outcome measure of this study.
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According to ACOG, there is insufficient evidence to outline the optimal frequency of
glucose monitoring but the general recommendation is four times daily, one fasting and then 1 or
2 hours postprandial (ACOG, 2013). The most recent American Diabetes Association (ADA)
guidelines for diabetes in pregnancy glucose monitoring targets are: fasting ≤95 mg/dL (5.3
mmol/L) and; one-hour postprandial ≤140 mg/dL (7.8 mmol/L) or two-hour postprandial ≤120
mg/dL (6.7 mmol/L) (ADA, 2016). These targets may result in hypoglycemia for some
individuals thus the ADA recommends, in these cases, less stringent targets based on clinical
experience and individualized care (ADA, 2016).
Postprandial glucose measurements are preferred over preprandial measurements. A
retrospective study of women with GDM experienced lower glycosylated hemoglobin values and
had fewer macrosomic babies when postprandial glucose values were used (Major, deVeciana,
Morgan, & Henry, 1993). In a follow up randomized trial of 42 women, de Veciana and
colleagues concluded that fasting and 1-hour postprandial glucose monitoring demonstrated
improved glycemic control and decreases in shoulder dystocia, hypoglycemia, macrosomia, and
cesarean delivery in comparison to preprandial glucose monitoring (de Veciana et al., 1995).
Medication. Women who cannot maintain blood glucose levels within target ranges or
women who have greater initial degrees of hyperglycemia may require pharmacological therapy.
Insulin is the first-line agent recommended for treatment of GDM in the U.S. (ADA, 2016). The
ACOG criteria for initiating insulin therapy include a fasting plasma glucose level >105 mg/dl
and 2-hour plasma postprandial levels >120 mg/dl (ACOG, 2013). If insulin is required, the
target plasma glucose levels are fasting glucose value 60–90 mg/dl, preprandial value 60–105
mg/dl, 2-hour postprandial value <120 mg/dl, and 1-hour postprandial value not >130-140 mg/dl
(ACOG, 2013; ADA, 2016).
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Pharmacologic therapy with oral agents such as glyburide and metformin are becoming
more popular. Randomized controlled trials demonstrate the efficacy and short-term safety for
mother and fetus when administering metformin (pregnancy category B) and glyburide
(pregnancy category B) although the potential for long-term adverse effects remains unclear
(Coustan, 2007; Langer, Conway, Berkus, Xenakis, & Gonzalez, 2000; Rowan, Hague, Gao,
Battin, & Moore, 2008). Metformin may be the preferable over insulin for maternal health but
holds a higher risk of prematurity (Balsells, Garcia-Patterson, Sol al Roque, Gich, & Corcoy ,
2015).
Outcomes. Studies exist that point to improved perinatal outcomes when treatment
includes nutrition therapy, blood glucose monitoring, and insulin therapy when needed. In a
study by Crowther and associates, 1000 women with GDM were randomized to an intervention
group (dietary advice, blood glucose monitoring, and insulin therapy) or routine care (Crowther,
Hiller, Moss, McPhee, Jeffries, & Robinson, 2005). The 490 women in the intervention group
experienced significant reductions in complications such as large for gestational age newborn,
shoulder dystocia, and perinatal death (1% vs. 4%, P= 0.01) (Crowther et al., 2005). Langer and
colleagues expressed similar findings in their matched controlled study of nondiabetic women,
women treated for GDM ,and women diagnosed with GDM after 37 weeks gestation (Langer et
al., 2005). Untreated women experienced a two to four fold increase in macrosomia and
metabolic complications (Langer et al., 2005).
Self-Management
Concept
The concept of self-management is widely used in the literature, yet it differs across
disciplines, programs of research, and authors (Ryan & Sawin, 2009). Self-management can be
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described as a group of daily behaviors that individuals perform to manage a condition (Glasgow
& Anderson, 1999). It is a dynamic process in which individuals and families engage in
processes to improve their health versus comply with prescribed orders (Ruggiero et al., 1997).
The vast majority of self-management research resides in chronic disease management
and has resulted in numerous self-management frameworks (Corbin & Strauss, 1988; Grey,
Knafl, & McCorkle, 2006; Lorig & Holman, 2003; Ryan & Sawin, 2009). Corbin and Strauss
(1988) categorized the chronic disease self-management (CDSM) behaviors into three realms:
(1) medical management, (2) adopting new behaviors, and (3) dealing with emotions. In 2001,
Lorig, Sobel, Ritter, Laurent, and Hobbs outlined five core self-management behaviors that are
seen in most chronic conditions: problem solving, decision making, resource utilization, forming
of a relationship with a provider, and taking action. Later, Lorig and Holman (2003) and Unger
and Buehlow (2009) further defined CDSM as the actions people take to manage their chronic
disease and its effects including medication and treatment compliance, safety, event
management, and lifestyle management.
Grey et al. (2006) expanded self-management knowledge by including the family in their
framework as well as suggest its application beyond those already diagnosed with a chronic
illness. The authors state that their framework provides an approach for “understanding,
development, and testing of self- and family-management interventions for people with chronic
conditions, or at risk for their development” (Grey et al., 2006, p. 281). Their Self and Family
Management Framework outline risk and protective factors along with outcomes of selfmanagement.
Ryan and Sawin (2009) further incorporate the family into their Individual and Family
Self-Management Theory (IFSMT). The IFSMT combines previous research on Ryan’s
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Integrated Theory of Health Behavior Change (ITHBC) and Sawin’s Ecological Model of
Secondary Conditions and Adaptation into one framework with context, process, and outcomes
dimensions. The context dimension includes risk and protective factors including physical and
social environment, condition specific factors, and individual/family characteristics.
The processes dimension of the IFSMT encompasses knowledge and beliefs, selfregulation of skills and abilities, and social facilitation. Ryan and Sawin (2009) include the
actual engagement of self-management behaviors as a proximal outcome of their Individual and
Family Self-Management Theory (IFSMT) while distal outcomes are health status, quality of
life, and cost of health.
While most of the existing research on self-management theory revolves around chronic
conditions, the IFSMT expands its utility into health promotion and more acute conditions. A
2013 study by Doering used the IFSMT when exploring the physical and social environment of
sleep self-management in postpartum women. In addition, Ryan and colleagues are currently
engaged in research on an osteoporosis prevention app using the IFSMT (NIH Reporter).
Recently, Shulman-Green et al., (2012) completed a metasynthesis of 101 selfmanagement articles to describe the processes of self-management. The authors identified three
categories of self-management processes: 1) focusing on needs due to the chronic condition; 2)
activating resources; and 3) living with a chronic illness (Shulman-Green et al., 2012). The
synthesis also outlined additional task and skills mentioned in the articles. It is surprising that
the use of computers, patient portals, or secure messaging was not a skill listed.
In this day in age of technology evolution and governmental financial incentives for EHR
use, it seems logical to research and incorporate technology into self-management frameworks.
There is a growing body of evidence that self-management interventions and programs improve

28

outcomes in individuals with chronic illnesses (Ryan & Sawin, 2009). Yet, little research exists
on the impact self-management interventions can offer for more acute conditions or health
promotion. This research will further expand the use of the IFSMT to the GDM population
incorporating self-management concepts using a PWP as a technology based intervention.
GDM Self-management
While the emphasis of treatment for GDM is on dietary modifications, exercise, and
blood glucose monitoring, a standard on how to implement strategies for successful selfmanagement is lacking. Literature on GDM self-management is primarily qualitative and
identifies themes associated with diagnosis and management of GDM and barriers or facilitators
to GDM self-management.
Themes. Several qualitative studies exist on the lived experience of women with GDM
(Abraham & Wilk, 2014; Devsam, Bogossian, & Peacock, 2013; Morrison, Lowe, & Collins,
2014). While the number of themes and titles varied among the studies, common themes in all
the studies revolved around initial shock and emotions with diagnosis of GDM, adapting to
GDM, social support, and staying healthy to prevent Type 2 diabetes.
Morrison and colleagues conducted a postal survey of the experiences of women with
GDM in Australia and outlined eight themes: 1) shock, fear, and anxiety, 2) uncertainty and
skepticism, 3) opportunity to improve one’s health, 4) adapting to life with GDM, 5) the need for
support, 6) better awareness, 7) abandoned, and 8) staying healthy and preventing diabetes.
Women taking insulin were more likely to feel shock, fear, and anxiety (p= 0.001).
Similarly, Abraham and Wilk (2014) conducted a phenomenological study of 10 women
with a history of GDM within the last five years. They identified five themes: 1) Authentic
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emotion; 2) Judgement; 3) It’s only a matter of time; 4) I can’t do this alone; and 5) Missed
opportunities.
Devsam et al. (2013) performed an interpretive review of women’s experiences with
GDM that incorporated both qualitative and quantitative research. Nineteen studies were
reviewed and three themes were identified: 1) Responses which included the core concepts of
initial response to GDM, negative thoughts about GDM, struggle to manage GDM, loss of
control, changes to identity, and adapting to change; 2) Focus of concern with core concepts of
concern for baby’s health, concern for own health, perceived seriousness of GDM, perceived fear
of Type 2 diabetes; and 3) Influencing factors with core concepts of cultural roles and beliefs,
social support and stigmas, professional support, adequate information, and barriers to self-care.
The authors propose using these themes as a guide when caring for women with GDM.
Facilitators/Barriers. Studies suggest that facilitators to health behavior change after
diagnosis of GDM are concern for the health of the baby, to stay healthy for the other children,
to be a role model for the children, and desire to avoid type 2 diabetes (Devsam et al., 2013 ).
Barriers identified in the literature include lack of motivation, lack of time, lack of clear
and timely information, and lack of interventions that fit into women’s multiple roles as
caregivers, workers, and patients (Parsons, Ismail, Amiel, & Forbes, 2014). The dietary and
activity modifications required may be difficult for many women due to their current lifestyle
habits and as a result many women struggle to adhere to GDM guidelines (Carolan, Gill, &
Steele, 2012; Hui et al., 2014).
Research findings suggest that effective glycemic control is a vital component to good
maternal and fetal outcomes, which is influenced by a woman’s self-management behaviors
(Carolan et al., 2010). While many women feel they have knowledge related to GDM, they often
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seek additional information through family, friends, and online sources. Women in the Hui et al.
(2014) study felt the dietary information they were given by providers was insufficient and was
not meeting their personal needs. Women felt frustrated about the limited amount of time they
had to adapt their lifestyle choices and they also felt the information was not tailored to them
specifically (Hui, 2014).
Recognizing the barriers and facilitators to GDM self-management is a first step to
designing interventions and programs to promote GDM self-management. Very few studies exist
in the literature related to GDM self-management interventions despite literature supporting the
value of GDM self-management on reducing obesity, reducing pregnancy complications, and
improving glycemic control (Cheung, 2009; Glastras & Fulcher, 2012). The majority of studies
focus on type of medical management including medication and the threshold for glycemic
control (Alwan et al., 2009).
GDM Interventions. To address this gap, Carolan (2015) conducted an integrative
review of the literature to guide GDM management. The goal of the review was to provide
background information for the development of future GDM management programs and
interventions. Twelve papers were reviewed and all of them used quantitative methods with
comparison groups (Carolan, 2015). The results of the review indicated that GDM interventions
fall into three categories: (1) self-monitoring of blood glucose levels, (2) dietary and exercise
interventions, and (3) behavioral interventions/counseling. These interventions reduced insulin
requirements, reduced macrosomia, and improved knowledge and pregnancy outcomes
(Brankston, Mitchell, Ryan, & Okun, 2004; Carolan, 2015; Hoppichler & Lechleitner, 2001;
Landon et al., 2009; Moses, Barker, Winter, Petocz, & Brand-Miller, 2009).
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Use of Technology. Most of the research on GDM self-management has been with inperson education and counseling (Mendelson, McNeese-Smith, Koniak-Griffin, Nyamathi, &
Lu, 2008; Murphy, Guilar, & Donat, 2004) despite the successful outcomes using telehealth and
PWPs among people with type 1 and type diabetes (Po, 2000). This author was only able to find
two studies related to the use of such technology for GDM self-management.
Ferrara et al. (2012) studied whether a referral to a nurse-based management program
that offered supplemental GDM care via telephone counseling on diet, activity and blood glucose
monitoring was associated with improved perinatal outcomes as defined by macrosomia low
birthweight babies, and postpartum glucose testing. This was a multicenter, retrospective study
of 12 medical centers with over 11,000 subjects. The results suggest that receiving care at the
centers with higher referral frequency (>70%) compared to those with lower referral frequency
(<30%) for telephonic nurse management for GDM was associated with decreased risk of
macrosomic infant and increased postpartum glucose testing (multiple-adjusted odds ratio, 22.96;
95% confidence interval, 2.56 –3.4 and multiple-adjusted odds ratio, 0.75; 95% confidence
interval, 0.57– 0.98) (Ferrara et al., 2012).
In the second study, Carolan, Steele, and Krenzin (2015) created a web-based GDM
intervention aimed at multi-ethnic women in Melbourne, Australia. A pretest/posttest design
explored the impact of the intervention on GDM self-management principles, knowledge of
GDM, and food values for 21 women with GDM using the Knowledge of GDM questionnaire.
Results suggested that the intervention was effective in improving knowledge scores but less
effective in improving food values and self-management principles. The Fisher’s Exact test Pvalue for the association between GDM score improvement and education was 0.294; the
association between food score improvement and education was 0.347; and the association
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between self-management score improvement and education was 0.170. The authors explain that
a misunderstanding of specific survey questions and interpretation of the web resource may have
contributed to the lower improvement noted in the self-management area (Carolan, Steele, &
Krenzin, 2015). Revisions will be made and the authors have plans for a clinical trial.
While the number of themes and titles varied among studies, common themes identified
in women with GDM revolve around initial shock and emotions with diagnosis of GDM,
adapting to GDM, social support, and staying healthy to prevent Type 2 diabetes. Furthermore,
facilitators to health behavior change after diagnosis of GDM include concern for the baby’s
health, desire to stay healthy for their other children, be a role model to their kids, and desire to
avoid type 2 diabetes (Devsam et al., 2013 ). These themes and facilitators offer insight into the
emotional journey and motivation for health behavior change among women with GDM.
Barriers identified in the literature such as lack of time, lack of clear and timely information, and
difficulty adjusting to diet modifications point to the struggles women with GDM experience and
should be addressed when designing future interventions to care for this population. Literature on
the interventions for GDM self-management revolve around three topics; self-monitoring of
blood glucose, diet and exercise, and behavioral interventions.
Web-based patient portals for GDM management have the potential to address the
facilitators and barriers noted above and could potentially provide a cost-effective alternative to
strictly in-person diabetes clinic visits. For instance, portals can be accessed at any time so
timely information could be a benefit of a portal designed for GDM management. The limited
existing research on PWP use and other health information technology interventions for GDM
self-management is worth further exploration and is the intent of this research study.
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Patient Web Portals
History
Patient web portals were first introduced and adopted by large health care organizations
in the late 1990s (Halamka, Mandl, & Tang, 2008). It was not until about 2006 that patient web
portals gained widespread use due to the launch of personal health records (ePHRs) by Microsoft
and Google and the general public’s adoption to communication sharing tools like social media
and smartphones (Weitzman, Kaci, & Mandl, 2009). Ultimately, the main driver of PWP
adoption and sustainability is the meaningful use (MU) criteria set forth by the Centers for
Medicare and Medicaid Services (CMS) EHR incentive program as part of the American
Reinvestment and Recovery Act of 2009 (Wright, Feblowitz, Samal, McCoy, and Sittig, 2014).
PWPs could be viewed as a transformative piece of technology that offers unlimited online
access to online health information and care however; simply building a PWP will not ensure its
use or success (National Learning Consortium, 2013; Weingart, Rind, Tofias, & Sands, 2006).
The PWP needs to be user-friendly, engaging, and structured in a manner that supports patientcentered outcomes. Furthermore, the PWP should be integrated into clinical practice so it
becomes part of the care delivery model and method to communicate with patients, provide
support, and information (National Learning Consortium, 2013).
Definition
A PWP is an interactive internet-based website that allows patients and providers to
communicate and give patients access to their medical record, review clinical data, graphs, and
education points (Sorensen, Shaw, & Casey, 2009). Patient portals are managed by a health care
institution or health care provider. The purpose of the portal concept is to engage patients in
actively participating in their health care rather than being passive recipients of care (Shaw &
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Ferranti, 2011). Irizarry, DeVito-Dabbs, and Curran (2015) describe a patient portal as an ePHR
[electronic personal health record] that directly links, or is “tethered” to an EHR (p. 2).
The HealthIT.gov (2016) definition is more specific stating that a patient portal is a secure
online website that gives patients convenient 24-hour access to personal health information from
anywhere with an Internet connection. While most of these definitions are similar in nature they
lack clarity on the specific components of a PWP.
HealthIT. gov’s definition includes a list of possible features that people can access
within the portal such as discharge summaries, medications, allergies, and lab results. They note
that some patient portals also allow patients to request medication refills, schedule appointments,
and secure message to healthcare providers (HealthIT.gov, 2013). Meaningful Use requirements
outline six specific functionalities of patient portals for their incentive program: (1) secure
messaging, (2) clinical summaries after visits, (3), patient specific education, (4) patient
reminders, (5) medication reconciliation, and (6) access to personal health information (Irizarry
et al., 2015).
Patient web portals (PWP) vary in their content and what is available for patients to view.
This lack of clarity on minimal components of a patient portal creates confusion when designing
a study or interpreting results. Each study may incorporate a different set of PWP features which
in turn could influence the results. Generalizing the results beyond a specific institution can be
difficult when common PWP features are not used.
PWP Users
Definition. Variations exist within the literature on definitions and categories of people
who use and don’t use patient web portals (Ronda et al., 2015; Sarkar et al., 2011; Weingart et
al., 2006; Yamin et al., 2011). The terms adopters and nonadopters were used in a 2011 study by
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Yamin and associates regarding personal health record (PHR) use. Adopters were those
individuals who registered for the PHR and activated their account while nonadopters did not
have an active account (Yamin et al., 2011). A 2006 study by Weingart and colleagues, describe
individuals as enrollees or nonenrollees of a patient portal called PatientSite. The terms users and
nonusers of PWPs is all cited in studies (Ronda et al., 2015; Sarkar et al., 2011). Ronda and
associates further classified patients into two groups: ‘early quitters’ and ‘persistent users’.
For the purposes of this study nonusers apply to subjects who logged in only once.
Short-term users were subjects who logged in during the first month after enrollment. Persistent
users were users that logged in throughout the third trimester.
While PWPs have shown to be an effective tool to promote diabetes self-management
and received an overall positive reception by patients, adoption rates vary (McMahon et al.,
2005; Ronda et al., 2015). Study results suggest that there are differences between users and
nonusers of PWPs in regards to demographic and other variables (Osborn, Mayberry, Wallston,
Johnson, & Elasy, 2013; Ronda et al., 2015). These differences are important to understand so
that PWP designs can be refined and individualized to meet the needs of specific individuals.
A case-control study of 200 patients by Weingart and colleagues (2006) found that
PatientSite enrollees were younger, more educated, and had fewer medical problems than
nonenrollees (P< 0.001). However, seven percent of users were at least age 65. Similar results
were also noted in a 2015 study by Ronda and associates. Ronda and colleagues administered a
survey to 1,500 type 1 and type 2 diabetes patients within 62 primary care clinics and one
hospital outpatient clinic. 632 patients (42.1%) responded to the survey. Their study on the use
of a diabetes PWP concluded that persistent users were younger (61.9 + 12.7 in early quitters vs.
58.5 + 13.3 for persistent users, P=.02), employed (36.3 for early quitters vs. 47.1 in persistent
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users, P= 0.01), and more often used insulin (45.9 in early quitters vs. 63.2 in persistent users,
P<0.001) (Ronda et al., 2015).
In contrast, a study by Sarkar (2011) of 14,102 adults with diabetes in Northern
California concluded that older adults, those with less education (OR compared to college
graduates, 2.3(1.9-2.7)) and African Americans and Latinos (OR 2.6(2.3-2.9); (OR 2.3(1.9-2.6))
were less likely to access a PWP. However; those with computer access, older adults were more
likely to use the PWP than younger adults. Interestingly, Mayberry and colleagues identified
family member support as a reason for why patients of all health and computer literacy levels
might access and use PWPs (Mayberry, Kripalani, Rothman, and Osborn, 2011).
Gender. Several studies indicate that women adopt PWP technology more quickly than
men (Fleming, Cullen, & Luna, 2015; Kruse et al., 2015). This result is likely due to women
having more interactions with the healthcare system. Even when reproductive visits (e.g.,
pregnancy, birth control) were removed, Courtenay noted that women are encouraged to pay
more attention to their health and seek routine care (Courtenay, 2009 as cited in Broom &
Tovey). Vaidya, Partha, and Karmakar (2012) also validated similar findings through a study that
found women to be the highest consumers of preventative health services, perceiving PWPs as
another form of preventative care and a way to stay updated about their health.
A review of 17 research studies by Emont (2011) on PWP use concluded that the
majority of consumers are female and the most used features of the PWP are secure messaging,
viewing lab results, scheduling appointments, and medication refill requests. Furthermore, the
author suggests that people become more engaged in their health and medical care when their
health information is accessible online (Emont, 2011). Certainly this information is encouraging
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to researchers of PWP intervention studies focused on women, particularly those focused on
women.
Outcomes. The use of patient web portals (PWP) as a tool to promote diabetes selfmanagement is prevalent in the literature (Fonda et al., 2009; Grant et al., 2008; Kim, Kim, &
Ahn, 2006; McCarrier et al., 2009; Quinn, et al., 2008). Many of the studies to date are
randomized controlled trials that focus on the biological outcomes of hemoglobin A1c levels,
blood pressure, and lipid levels (Fonda et al., 2009; Grant et al., 2008; Kim, Kim, & Ahn, 2006;
McCarrier et al., 2009, McMahon et al., 2005; Noel, Vogel, Erdos, Cornwall., & Levin, 2004;
Quinn et al., 2008).
Several randomized and nonrandomized controlled studies demonstrate a decrease in
hemoglobin A1c levels with PWP use (Fonda et al., 2009; Grant et al., 2008; Kim et al., 2006;
Quinn et al., 2008). See Table 3 for specific details on each study and results. Conversely,
reductions in blood pressure and lipid levels with PWP use are not as conclusive nor are they as
relevant in the gestational diabetes population (Grant et al., 2008; McMahon et al., 2005; Shaw
& Ferranti, 2011).
Research has also shown that PWP use is associated with lower diabetes distress scores.
For example, a randomized controlled trial of 102 patients with type 1 and 2 diabetes found
lower diabetes distress in subjects who used their PWP and the lowest diabetes distress scores
among more frequent PWP users (Fonda et al., 2009). Diabetes distress scores were measured at
baseline and quarterly for 12 months using the Problem Areas in Diabetes (PAID) questionnaire.
The PAID scores of sustained, regular users of the PWP were 14.7 points lower that subjects
who did not use the PWP (P=0.006).
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Additionally, research exists related to the components of diabetes self-management such
as self-efficacy and PWP use. McCarrier and colleagues (2009) conducted a randomized
controlled trial of 77 patients with type 1 diabetes to determine if a web-based case-management
program in an EHR could improve glycemic control and diabetes-specific self-efficacy. The
intervention group experienced a significant increase in diabetes-related self-efficacy compared
to the usual care group (group difference of 0.30; 95% confidence interval 0.01 to 0.59; P =
0.04). Self- efficacy is a key component to self-management (Ryan & Sawin, 2009).
Research Gaps
While studies exist related to counseling and educational programs for GDM selfmanagement, only one study was found in the literature on the use of a PWP for GDM selfmanagement (Carolan, et al., 2015). Patient web portals have successfully been used to promote
self-management in patients with type 1 and type 2 diabetes resulting in improved hemoglobin
A1c levels (Kim et al., 2006; McMahon et al., 2005; Noel et al., 2004; Shaw & Ferranti, 2011;
Smith et al., 2004). This concept should be tested in the GDM patient where motivation is high
and barriers to self-management include time and travel (Carolan et al., 2012). Effective GDM
self-management interventions have the potential to control glucose levels and reduce the risk of
adverse outcomes for mothers and babies during pregnancy and later in life.
Unfortunately, few intervention studies have been performed on this population of
women. Most of the literature is qualitative in nature and points out facilitators and barriers to
GDM self-management. There is solid evidence on the negative consequences for the mother
and infant in terms of GDM and the importance of dietary modifications, exercise, and tight
blood glucose monitoring. In addition, evidence suggests and recognizes the need for resources
and programs to promote GDM self-management (Carolan et al., 2010). However there is a gap
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in the literature on how best to promote GDM self-management, what resources and technology
are most effective.
Furthermore, little is known about the patient characteristics of users and nonusers of
PWPs and patterns of use (Jones et al., 2015). Understanding how women with GDM use PWP
is essential to refining this technology to further meet the needs of the patients, providers, and
clinicians.
Chapter Summary
This chapter discussed the physiology, negative effects of GDM, and its management
course to provide a foundation of evidence to this study topic. The concept of self-management
and literature related to self-management for GDM was explicated. The literature on diabetes
self-management with a focus on the use of technology was examined as was the literature on
use of such technology for GDM self-management. Finally, literature on PWPs were synthesized
including definitions, specific populations of users, and outcomes of PWP use in type 1 and type
2 diabetes. Research gaps were identified and the rationale for additional research related to
GDM self-management using a PWP is outlined.
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Chapter 3
Methods
Research Design
The study was a retrospective cohort design that followed participants from entry into a
diabetes and pregnancy clinic between 28 to 32 weeks gestation through childbirth, accounting
for roughly a three month period of time. All patient care data and communication regarding the
patient’s GDM care are documented within the same electronic health record (EHR).
A retrospective design was used for several reasons. First, a prospective study would
involve a great deal of time in order to obtain an adequate sample size (Polit & Beck, 2012). The
health care organization for this study cares for a total of about 100 women with GDM a year,
which means a prospective approach would require recruiting patients for over two years and
then tracking them for the last three months of their pregnancy. With an estimated sample size
for an experimental or quasi experimental design of 200 subjects the data collection period of a
prospective study could be even longer. A retrospective design provides a large sample size in a
feasible amount of time.
Setting/Sample
The sample included all pregnant women in their third trimester with a diagnosis of GDM
according to the International Classification of Diseases, ICD-9 and ICD-10 codes that were
referred to and received services at a diabetes and pregnancy clinic in two hospitals in a
Midwestern state in the United States. The women received health care at the clinic between
January 2013 and January 2016.
Inclusion criteria were the following: (a) age 18 years and older, (b) diagnosis of
gestational diabetes (insulin or diet controlled), (c) in the third trimester of pregnancy but before
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32 weeks gestation, and (d) singleton pregnancy. Exclusion criteria were (a) women who first
presented to the clinic after 32 weeks gestation due to the decreased ability to impact blood sugar
numbers with less than three months of care, and (b) multiple gestation.
An estimated sample size of 300 women was targeted for this study. A power analysis
was conducted using G*Power software indicating a sample size of 128 was needed with 80
percent power for detecting a medium sized effect with 0.05 significance level assuming two
groups (users and nonusers) in the ANOVA model (Faul, Erdfelder, Lang, & Buchner, 2007). A
sample size of 159 was needed with 80 percent power for detecting a medium sized effect with a
0.05 significance level if there were three groups (nonusers, short-term users, persistent users) in
the ANOVA model. This power analysis was performed and validated by Dr. Weiming Ke,
University of Wisconsin-Milwaukee College of Nursing.
Data Source
The data sources for this study included a departmental Excel database, Epic EHR, and
the MyChart server log files. Epic’s MyChart is the PWP portion of the Epic system. Epic’s
MyChart is the most widely used patient portal according to a recent KLAS survey (Pennic,
2012). This healthcare organization has been utilizing Epic and portions of MyChart since
October 2011.
Patient Web Portal
Patients were able to activate their PWP by creating a username and password. Once
activated, the patients were able to view their health information and utilize the features of the
PWP. All women receiving care at the diabetes and pregnancy clinic received a log-in to access
the PWP for health care purposes. At their first visit in the clinic, women were asked about
enrollment and encouraged to consider enrollment if they have not already. Nurses at the clinic
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assisted patients who were interested in enrollment to sign up at the time of their visit or patients
were provided a code to enroll at their convenience at home. The code was printed on their
patient instructions and given to them after the visit. Patients were instructed that communication
between the staff and patients could occur via secure messaging, blood glucose numbers could
be entered into the flowsheet tab in MyChart or communicated through secure messaging or
phone/fax, and explanation was given about lab results and AVS instructions.
After an account was established, patients could login to the PWP to access various
information and features including laboratory results, appointment reminders, medication refill
requests, blood sugar flow sheets, patient instructions, and secure messaging. All communication
between the patient and provider are stored in the EHR. The specific features included in this
study are further discussed in the variables and measurements section. This section does warrant
discussion on how each PWP feature is utilized in the diabetes and pregnancy clinic.
Appointment reminders are sent automatically through MyChart for each diabetic visit
confirming the appointment date, time, location, and any special instructions. The AVS provides
patient instructions and medical information to the patient via MyChart after each diabetic visit.
The AVS for the diabetic visits used a standard template of problem list, allergies, diagnosis,
medications and treatment team for all patients. In addition, there are patient specific instructions
and education that are included in the AVS specific to the diabetic patient and that visit which
may include specific patient goals or dietary instructions and follow-up. The AVS is typically 3
pages or longer in length. The lab results section allows patients to review their lab results,
specifically hemoglobin A1c and glucose tolerance test results as a specific result and trending
over time. Medication refills is a request to the provider to refill a prescription which in this case
would be insulin. The blood glucose flowsheet was built to have patients submit their blood
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glucose numbers via MyChart and then be electronically filed. Finally, the secure messaging
feature allows the patient to communicate with the nurse or provider via MyChart to ask
questions, send blood glucose information, or seek clarifications. The workflow in the diabetes
and pregnancy clinic is to respond to these messages on a daily basis.
Use of the PWP was in addition to routine care within the clinic. Routine care typically
consisted of diabetes visits every two weeks with the certified diabetic nurse educator, then
weekly at 36 weeks and thereafter until delivery unless otherwise specified by the provider.
All patient level usage of Epic MyChart was timestamped and stored in the
organization’s server log files. The server files provided time information and frequency of PWP
use regarding each feature of the PWP for purposes of this study.
Procedures for Data Collection
After IRB approval was obtained, a report from the healthcare organization’s data
warehouse was created by IT analysts of all women who sought care in the diabetes and
pregnancy clinic between January 2013-January 2016 with a diagnosis of GDM and who met the
inclusion criteria. The report excluded women who did not meet the inclusion criteria. In
addition, the IT analysts created a report from the MyChart server log files that provided the
PWP activity by each woman as defined by the number of hits to a particular feature of the PWP.
This report was used to separate subjects into three groups- nonusers, short-term users, and
persistent users. It also served as the data source for PWP usage. It captured the date and time of
each activity to a PWP feature by individual over the third trimester of pregnancy. The usage
report was exclusive to the PWP activity within the diabetes and pregnancy clinic and the GDM
diagnosis and not the user’s PWP use in general. The data was then categorized according to the
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PWP feature accessed, number of hits, and over what period of time to establish the pattern of
use. The data was then imported into SPSS.
A second report was created by an IT analyst from Epic based on the inclusion criteria
that outlined the patient characteristics per individual. Target blood glucose levels for each
woman collected via the PWP, telephone, or office visit, were gathered by the PI via a hospitalbased Excel database. The percentage of blood glucose levels within target range for each
woman per month were entered into the SPSS spreadsheet.
All data was stored on a personal, password protected laptop in a locked office. The initial
reports required a patient’s name and MRN number so the PI could match the blood glucose
levels, PWP activity, and patient characteristics to the correct patient. Once files were merged,
the subject was assigned a number and the data became de-identified. The legend of the patient
name and assigned number was stored in a separate file outside of SPSS in a locked file cabinet.
A codebook was developed and stored electronically in SPSS.
Study Variables and Measurements
The study variables included measures of (a) patient characteristics, (b) PWP features and
patterns of use, and (c) targeted blood sugar achievement.
Patient Characteristics. A set of patient characteristics was collected for all subjects.
These characteristics were collected at the entry point into the study which was the first visit to
the diabetes in pregnancy clinic. Some of the variables, (e.g. race and ethnicity) may have been
documented in the EHR prior to referral to the clinic, and the most recent entry was used. Age,
race, ethnicity, marital status, insurance, and employment were abstracted from the
demographics section of the EHR in the data warehouse. Clinical data such as BMI, type of
GDM, and number of pregnancies with GDM, were abstracted from the clinical flowsheets and
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documentation within the EHR. More specifically, they were abstracted from the prenatal
flowsheets at the point of the first diabetes in pregnancy clinic visit. Conceptual and operational
definitions for each variable are described in Table 4.
PWP Features. Since PWPs features are not standardized across institutions, each
feature was defined and outlined for this study. The features included for this study were
patient/provider messaging, flowsheets/blood sugar logs, after visit summaries/ instructions, labs,
appointment reminders, and medication refills. Conceptual and operational definitions for each
of these variables are outlined in Table 4.
Each feature was analyzed based on the frequency and pattern of use during the third
trimester of pregnancy. Access to each feature was reported in whole numbers. The starting
point was the date of the patient’s first diabetes in pregnancy appointment and terminated at the
date of delivery. To expedite the abstraction process a report was created from the MyChart web
server log files that produced the number of times a PWP feature was accessed, what was
accessed, and the date/time for each woman during the study period.
PWP frequency. The number of times that each patient logged into the PWP and the
number hits for each feature they used per login session was captured. Frequency of use was
measured by the number of “hits” or times the patient accessed a feature of the PWP. This may
include more than one “hit” within the same minute. All “hits” were included in the data.
For the purposes of this study, the category “ nonusers” applied to subjects who logged in
only once. “Short-term users” were women who logged in during the first month after
enrollment but not thereafter. “Persistent users” were users that logged in throughout the third
trimester.
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PWP patterns of use. This study also examined user’s patterns of PWP use during the
third trimester. A “pattern of use” is defined as the utilization of PWP features from first
appointment in the diabetes in pregnancy clinic to the time of delivery. It includes frequency and
consistency of PWP use. Duration of use was unable to be captured. Frequency of PWP use was
defined as the PWP features accessed and the number of hits on each feature over the study
period. Consistency was measured in hit days and hit months. Hit day was any day that the
patient accessed the PWP in the third trimester regardless of the number of times accessed that
day or features accessed. Hit month captured any individual month where the patient accessed
any feature of the PWP at least once.
Target blood glucose levels. Target blood glucose levels were measured using the
percent of blood glucose levels reported each month within target range per subject. Target
blood glucose levels were identified as less than 125 mg/dL for fasting and post-meals. A
fasting plasma glucose level >126 mg/dl (7.0 mmol/l) or a casual plasma glucose >200 mg/dl
(11.1 mmol/l) meets the threshold for the diagnosis of diabetes, if confirmed on a subsequent
day, and precludes the need for any glucose challenge (ADA, 2003). All reported blood glucose
levels for the month were recorded into a hospital password protected shared folder and then a
percentage is calculated monthly using the number of blood sugars reported within target range
divided by the total number of blood glucose levels reported. This process is repeated monthly
during the third trimester until delivery.
Plans for Data Analysis
The data were analyzed using SPSS version 23. To answer aim 1, descriptive statistics were
performed using a frequency table including mean and standard deviations as well as
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independent t-tests on the continuous variables of age and pre-pregnancy BMI. A Pearson’s chisquare test of independence was performed on all categorical variables using cross tabulation.
To answer aim 2, categorical variables were expressed as percentages and continuous
variables as means with standard deviation (SD) and range. A histogram was generated to assess
distribution, and then skew was calculated (Meyers, Gamst, & Guarino, 2013). Independent ttests were performed for age and pre pregnancy BMI between PWP users and nonusers, and chi
square tests were conducted on the remaining patient characteristics.
To answer aim 3, a repeated measures ANOVA was performed to compare glycemic control
between users and nonusers. Groups included users and nonusers. The intervention was PWP
use with the outcome variable being glycemic control. Glycemic control was measured monthly
over the third trimester. An F-statistic was calculated and an alpha of 0.05 was used.
Human Subjects/Institutional Review Board
Institutional Review Board approval was obtained through the University of WisconsinMilwaukee (UWM). An application of deferral was completed and granted in September 2016
from ProHealth Care to defer all IRB activities for this study to UWM. The ProHealth Care
deferral is located in Appendix A. The UWM IRB approval can be found in Appendix B.
Summary of Chapter
This study used a retrospective cohort design to address the following research aims: 1)
compare the characteristics of nonusers and users of a patient web portal (PWP) for selfmanagement including relationships between characteristics and PWP use/nonuse, 2) in users of
the PWP, describe the frequency and patterns of PWP use and, 3) compare glycemic control
between PWP users and nonusers. The data sources for this study included the Epic EHR,
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MyChart server log files, and a departmental Excel database. Data collection methods are clearly
outlined along with data analysis techniques to elicit the best outcomes for the study questions.
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Chapter 4
Results
Between January 2013 and January 2016, 181 patients met the inclusion criteria. Of the
181 patients, 23 patients were further excluded from the analyses due to lack of data on target
blood sugars (meaning there were no data for any months within the third trimester) (n=17) or
they were a duplicate patient (n=6). Patients with more than one pregnancy during the three year
study timeframe were included and captured as a separate subject for each pregnancy. In other
words if a patient had a pregnancy in 2014 and met the inclusion criteria, her data was captured
for 2014. If she also had a subsequent pregnancy in 2016, and again met the inclusion criteria,
her 2016 data was captured and analyzed as well but, the data was recorded as a separate
occurrence. This was the case for 2 records. Of the 158 patients with complete data for analysis,
6 (4%) were considered short-term users, 85 (54%) were persistent users, and 67 (42%) were
nonusers. Due to the power analysis discussed in the methods section suggesting the need for a
minimum of 159 patients with 80 percent power for detecting a medium sized effect with a 0.05
significance, short-term users and persistent users were combined into a single user group. The
final groups consisted of 67 (42 %) nonusers and 91 (58%) users.
Results for Aim 1
Research aim 1 sought to compare the characteristics of nonusers and users of a patient
web portal (PWP) for self-management including relationships between characteristics and PWP
use/nonuse (see Table 5).
Users of the PWP were more likely to be employed fulltime and this difference was
statistically significant (p= .011). Marital status was somewhat similar between the groups with
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50 (74.6%) of nonusers and 74 (81.3%) of users being married and 28 (17.7%) of nonusers and
14 (20.9%) of users being single. Similarly, the chi- square test illustrates that there is not a
statistically significant difference in marital status between users and nonusers of the PWP
(p=.522). Two categories of marital status, divorced and significant other, had expected counts
less than five. Legally separated and widowed were zero for both PWP users and nonusers.
No statistically significant difference existed between users of the PWP and nonusers for
history of previous pregnancies with GDM (p= .192), although a greater percentage of users had
no prior history of GDM in a previous pregnancy (71.1%) versus nonusers (61.2% ). Similarly, a
greater percentage of users had diet controlled gestational diabetes [n=76 (83.5%)] than did
nonusers [n=50 (74.6%)] however; this was not statistically significant (p=.169). Most patients
had private insurance with a greater percentage noted in the user group [n=79 (86.8%)] versus
the nonuser group [n=51 (76.1%)]. Nine (13.4%) of nonusers and five (5.5%) of PWP users did
not have an insurance type on file.
This study sample was homogenous in terms of race. One hundred twenty five of the 158
subjects (79.1%) noted their race as White/Caucasian with a greater percentage being users of
the PWP [n=78 (85.7%)] compared to nonusers [n=47 (70.1%)], (p=.023). While statistically
significant, there were numerous expected counts less than five when performing the chi-square
test. The same holds true for ethnicity (p= < .001).
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Table 5
Patient Characteristics of PWP Users and Nonusers for GDM self-management
Total
Age (mean)
Race
White/Caucasian
Black/African American
Asian
Hispanic
Hawaiian/Pacific Islander
American Indian/Native
Alaskan
Other
Unknown
Ethnicity
Nonhispanic Latino
Hispanic/Latino
Patient chose not to answer
Marital Status
Married
Single
Divorced
Significant Other
Legally Separated
Widowed
Insurance
Public
Private
Not reported
Employment
Fulltime
Part-time
Self employed
Not employed
Prepregnancy BMI (mean)
Type of GDM
Diet controlled
Insulin
Prior pregnancy with GDM
No
Yes

N=158
N=158
125 (79.1%)
4 (2.5%)
16 (10.1%)
3 (1.9%)
0 (0%)
0 (0%)
6 (3.8%)
4 (2.5%)
N=158
137 (86.7%)
19 (12.0%)
2 (1.3%)
N=158
124 (78.5%)
28 (17.7%)
5 (3.2%)
1 (0.6%)
0 (0%)
0 (0%)
N=158
14 (8.9%)
130 (82.3%)
14 (8.9%)
N= 158
89 (56.3%)
18 (11.4%)
5 (3.2%)
46 (29.1%)
N=152
N=158
126 (79.7%)
32 (20.3%)
N= 157

Nonusers
N=67
31.1 (SD 4.30)

Users
N=91
30.5 (SD 4.24)

47(70.1%)
1(1.5%)
8 (11.9%)
3 (4.5%)
0/0%
0/0%

78 (85.7%)
3 (3.3%)
8 (8.8%)
0 (0%)
0 (0%)
0 (0%)

4 (6.0%)
4 (6.0%)

2 (2.2%)
0 (0%)

(p-value)
.411
.023

< .001
49 (73.1%)
16 (23.9%)
2 (3.0%)

88 (96.7%)
3 (3.3%)
0 (0%)
.522

50 (74.6%)
14 (20.9%)
2 (3.0%)
1 (1.5%)
0/0%
0/ 0%

74 (81.3%)
14 (15.4%)
3 (3.3%)
0/ 0%
0/0%
0/ 0%
.164

7 (10.4%)
51 (76.1%)
9 (13.4%)

7 (7.7%)
79 (86.8%)
5 (5.5%)
.011

28 (41.8%)
9 (13.4%)
2 (3.0%)
28 (41.8%)
28.6 (SD 6.16)

61 (67.0%)
9 (9.9%)
3 (3.3%)
18 (19.8%)
29.6 (SD 6.74)

50 (74.6%)
17 (25.4%)

76 (83.5%)
15 (16.5%)

41 (61.2%)
26 (38.8%)

64 (71.1%)
26 (28.9%)

.322
.169

.192

Note. SD= standard deviation.
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The histogram examining age in users and nonusers demonstrated a fairly normal
distribution (see Figure 3). The skewness for nonusers was -.43 and the skewness for users was .40 both within the conservative acceptable threshold of +.5 for normality (Meyers et al., 2013).
The mean age of nonusers (with standard deviations in parentheses) was 31.1 (4.30) and ranged
from 20 to 42 years. Users of the portal ranged from 18 to 40 years of age with a mean of 30.5
(4.24).
Figure 3. Histograms Showing Frequency Count of Age with Normal Curve Superimposed
among Users and Nonusers of the PWP
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The mean pre-pregnancy BMI was 28.6 (6.16) for nonusers and 29.6 (6.74) for users. The
skewness for pre-pregnancy BMI was greater than age for both users and nonusers of the PWP.
Skewness for nonusers was .542 and .601 for users. Despite this, the histogram displayed a fairly
normal distribution for pre-pregnancy BMI in both groups (Figure 4). Of note, one missing value
existed for pre-pregnancy BMI in the nonuser group and five missing values existed in the user
group.
Figure 4. Histograms Showing Frequency Count of Pre-pregnancy BMI with Normal Curve
Superimposed among Users and Nonusers of the PWP
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An independent t-test was also conducted on the age and pre-pregnancy variables. For
both age and pre-pregnancy BMI, the Levene’s test for Equality of Variances p > .05 so the
equal variances assumed line was utilized for analysis. The results suggest that there was no
significant difference in age for nonusers (M=31.10, SD= 4.30) and users of the PWP (M=30.54,
SD= 4.24), t(156)= .82, p= .411. Additionally, there was not a statistically significant difference
in pre pregnancy BMI between nonusers (M= 28.57, SD= 6.16) and users of the PWP (M=
29.62, SD= 6.74), t(150)= .993, p =.322
Table 6
Independent T-Tests for Age and Pre-pregnancy BMI among PWP Users and Non-users
F

Sig.

t

df

Sig. (two-tailed) Mean dif. Std. Error
Diff.

Age at first visit
Equal variances assumed

.003

.954

Equal variances not assumed

.824

156

.411

.566

.687

.823

141.37

.412

.566

.688

-.993 150

.322

-1.06

1.06

-1.00 145.44

.316

-1.06

1.05

Pregravid BMI
Equal variances assumed
Equal variances not assumed

.250

.618

Note. Sig.= significance; dif.= difference; Std= standard
Results for Aim 2
Aim 2 sought to describe the frequency and patterns of PWP use in users of the PWP.
The PWP was accessed 4,870 times by the 91 users over the study period from January 2013Januray 2016. Descriptive statistics for each PWP feature are reported in Table 7. Three outliers
were excluded from the analysis, resulting in 88 users. The most commonly used PWP feature
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was the appointment reminders with a mean of 24.31 (SD 25.05) hits with a broad range from 0
to 93 hits. Of note, three patients accessed this feature more than 100 times and were excluded
from the analysis. The after visit summary (AVS) was the second most frequently accessed
feature during the third trimester of pregnancy with a mean of 15.44 (SD 17.00) ranging from 0
to 67. One patient was noted to have reviewed the AVS more than 100 times and was excluded
from the analysis. Labs, secure patient messaging, and flowsheets were accessed less frequently
and many people did not access these features at all. No patients utilized the insulin refill feature
of the PWP (n=15).
Table 7
Frequency of Use Related to Specific Features of the PWP
PWP feature

n

Min

Max

Mean

Mode

SD

Appt reminder

88

0

93

24.31

1

25.05

AVS

88

0

67

15.44

3

17.00

Labs

88

0

23

2.47

0

3.36

Flowsheet

88

0

30

1.31

0

5.02

Pt message

88

0

11

.35

0

1.46

Insulin refill

88

0

0

.00

0

.000

Note. Min= minimum; Max= maximum; SD= standard deviation; Pt= patient; Appt=
appointment; AVS= after visit summary
Patterns of PWP use were also measured in terms of consistency. Hits were any days that
the patient accessed the portal regardless of the number of hits within that day. Hit month was
any month that the patient accessed the PWP at least once in that month. Again, wide variation
existed in terms of individual access as noted in Table 8.
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Table 8
Consistency of PWP Use among PWP Users
Min

Max

Mean

Mode

SD

Hits/day

1

61

13.60

6

10.16

Hits/month

1

3

2.76

3

.06

______________________________________________________________________________
Note: n=91; Min= minimum; Max= maximum; SD= standard deviation
Duration or length of time spent on each PWP feature was unable to be measured in this study.
The most common time of day that the PWP was used was between 0801 and 1200, followed by
1201 and 1600. See Figure 5 for breakdown of PWP access by time of day.
Figure 5. Frequency of PWP Access Throughout the Day Over the Third Trimester
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Due to the low usage overall, it was difficult to establish additional patterns of use. As
noted earlier, six users only accessed the PWP for the first month. Four users only accessed the
PWP once after initial log in while one person accessed features within the PWP 319 times.
Results for Aim 3
Aim 3 sought to compare glycemic control between PWP users and nonusers. A repeated
measures ANOVA was conducted to compare the effect of PWP use (IV) on percentage of blood
glucose levels at month one, two, and three of the third trimester of pregnancy (DV). Target
blood glucose levels were measured as the percentage of reported blood sugars per subject that
was less than 125 mg/dL each month. The mean target blood glucose levels for nonusers of the
PWP was similar to that of users however; users of the PWP continued to see improvement over
all three months of the last trimester. Descriptive statistics for users and nonusers of the PWP are
outlined in Table 9.
Table 9
Descriptive Statistics for Target Blood Glucose Levels among PWP Users and Nonusers

Nonusers

Users

Month

Mean

Min

Max

SD

1

76.0

23

100

17.4

2

84.1

30

99

13.6

3

82.8

27

100

13.9

1

79.1

21

100

17.9

2

83.0

29

100

13.8

3

84.4

25

100

15.2

Note: Min=minimum; Max= maximum; SD= standard deviation
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A Mauchly’s Test for Sphericity was performed. This test assesses for the assumptions that
the levels of within-subjects variable display equal variances and the variances are the same at each
point (Meyers et al., 2013). The Mauchly’s Test of Sphericity indicated that the assumption of
sphericity was violated, [X2 (2) = 47.494, p < .001] therefore, the Greenhouse-Geisser correction was
used to generate sphericity-corrected F ratios. The Greenhouse-Geisser correction in the Tests of
Within-Subjects Effects determined that the percentage of blood glucose levels within target range
differed significantly over the three months (F (1.520, 191.474) = 1946.330, p= < .001) but did not
differ significantly between PWP users and nonusers (F (1.520, 191.474) = 184.428, p=.559) . The
between groups test also indicates that there was not a statistically significant difference between
PWP users and nonusers. The estimated marginal means graph (Figure 6) illustrates the

improvement of target blood glucose levels in both PWP users and nonusers over time. There
was a small decrease in target levels in the third month for nonusers that were not apparent in the
PWP user group.
Figure 6. Estimated Marginal Means for Target Blood Glucose Between PWP Users and
Nonusers
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Note. Tbs= target blood sugars (blood glucose levels); Month= month 1, 2,3 of third trimester.
Target blood glucose levels were measured as the percentage of reported blood sugars per
subject that was less than 125 mg/dL each month .
Chapter Summary
Data analysis was performed on a total of 158 women. This number was insufficient to
divide the sample into the original three groups of nonusers, short-term users, and persistent
users. As a result, short-term users and persistent users were combined into one group which
resulted in 91 users and 67 nonusers. There were no statistically significant differences between
PWP users and nonusers for age, pre pregnancy BMI, marital status, insurance, history of
previous pregnancy with GDM, or type of GDM. A significant difference was noted for race and
ethnicity but skewed by the numerous expected counts less than five in the analysis. There was a
statistically significant difference between employment status among PWP users and nonusers
with PWP users more likely to be employed fulltime and nonusers more likely to not be
employed.
Users of the PWP tended to access the portal each month in the third trimester. However,
consistency on the number of individual days in which the PWP was accessed varied greatly
with the greatest number of patients accessing the PWP on six individual days throughout the
third trimester. PWP users accessed the portal most frequently during the day between 08001200 and 1200-1600. The most frequently accessed features within the PWP were the AVS and
appointment reminders. Finally, the percentage of blood glucose levels within target range differed
significantly over the three months but did not differ significantly between PWP users and nonusers.
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Chapter 5
Discussion
Patient web portals are increasingly being used to assist with diabetes self-management
and have become a focus for meaningful use incentives and engaging patients in their care.
Limited research exists on the use of PWPs for GDM self-management. This study attempted to
address this gap by describing the patient characteristics of users and nonusers of a GDM PWP,
explore patterns of PWP use, and determine relationships between PWP use and glycemic
control.
Patterns of Use
Patterns of use were measured through frequency, consistency of use, and time of day.
As noted in the results section, the PWP features were accessed 4,870 from January 2103January 2016 among 91 patients. There appears to be a wide range of use among the various
features of the PWP with appointment reminders being the most frequently accessed followed by
the AVS. Medication refills were not accessed at any point by any patient in this study.
Although the majority of patients in the study were diet controlled, there were still 15 women on
insulin who used the PWP, yet none of them requested a medication refill through the PWP. A
plausible reason for this is the short duration in which insulin is prescribed. A patient may not
need to request a medication refill if the original prescription was dispensed in an amount that
could last three months by which point she gave birth and the GDM resolved.
Secure messaging was also used infrequently, which is incongruent with other studies.
In fact, secure messaging and prescription refill requests are the most commonly accessed PWP
features in many studies (Halamka et al., 2008; Silvestre, Sue, and Allen, 2009; Yamin et al.,
2011). A possible reason for the decreased use of secure messaging in this study may be the
frequent appointments that are involved with managing GDM. If questions are answered during
61

the appointment visit, there may be less reason to use secure messaging. That being said,
frequent communication of blood glucose levels between the patient and diabetic educator is
necessary to promote optimal blood glucose control and decrease maternal-fetal complications..
Secure messaging could be one method of this communication.
The consistency of PWP use showed most patients accessed the PWP over all three
months in the third trimester. Variation existed among patients in terms of the number of
individual days they accessed the PWP ranging from 1 to 61 days. Most patients accessed the
PWP a total of six days throughout the third trimester. Other studies on PWP use in this
population have not reported on this, which offers new insight into PWP use for patients with
GDM. It appears that women with GDM who use the PWP do so over the course of the third
trimester, which suggests that PWPs may provide health care providers with an opportunity to
target information throughout the last three months of pregnancy to optimize blood glucose
levels.
PWP Use and Glycemic Control
While there was not a statistically significant difference in target blood glucose levels
between PWP users and nonusers, the findings do illustrate improvements in target blood
glucose levels in both groups over time. This would be expected given a well-established current
educational program and frequent provider contact to assist with GDM management for pregnant
women. Studies conducted in Australia and the United States demonstrated fewer perinatal
complications, lower birthweights, and less preeclampsia in women who engaged in counseling
and treatment programs specific to GDM (Crowther et al., 2005; Landon et al., 2009).
Interestingly, the nonusers only saw the improvement in the third trimester from month
one to month two and then had a slight decline in month three. Moreover, the target blood
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glucose levels of PWP users improved steadily over the three months, beginning in month one
with a higher blood glucose percentage and ending with a higher blood glucose percentage in
month three than nonusers. These differences cannot be directly attributed to PWP use, but
suggests that further investigation into these differences should occur.
Patient Characteristics
Except on the variable of employment, users and nonusers of the PWP did not display
significant differences in terms of patient characteristics. There was a statistically significant
difference in employment status between users and nonusers of the PWP; however; the results
should be interpreted cautiously, since some of the categories of patient characteristics had fewer
than 5 responses. Users were more likely to be employed fulltime. These results support a
previous Italian study conducted by Scailoli and colleagues (2015) whereby pregnant women
who were employed more often used the internet for health related information pertinent to
pregnancy. In addition, these findings align with Kaptein and associates (2014) who concluded
women with GDM desired education and care that minimized travel and time commitments.
Similarly, Parson and colleagues (2014) identified several barriers to GDM management that are
relevant to fulltime employment including lack of time, lack of clear and timely information, and
lack of interventions that fit into women’s multiple roles as caregivers, workers, and patients.
Fulltime employees may find PWPs as a means to overcome some of these barriers. The PWP
was most frequently accessed between the hours of 0800-1200. These results may speak to the
accessibility of the PWP at a time when many people are at work.
Users and nonusers of the PWP primarily identified themselves as non-Hispanic white.
The results of this study do not suggest a significant difference in insurance type among users
and nonusers of the PWP. These findings are incongruent with some of the literature that
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suggests a “digital divide” exists among users and nonusers of PWPs. Previous studies by Laz
and Bereson (2012) and Yamin et al. (2011) found a significant difference between PWP
adoption rates with white patients adopting the PWP and internet significantly more than other
racial and ethnic groups. Future analysis using a larger sample size should be conducted to
validate the findings of this study for women with GDM.
Pertinent clinical related history did not appear to play a role in PWP use. Pre-pregnancy
BMIs were fairly consistent among the user and nonuser groups as was the type of GDM. This
was similar to findings in a study by Jones et al. (2015) regarding PWP use in 2,282 patients with
cardiovascular disease and/or diabetes who sought care at Geisinger’s primary care clinics. The
mean BMI was 31.36 in the nonuser group and 31.34 in the user group. The Jones et al. study did
not outline diabetes type in their results.
The results of this author’s study mirror. the total sample with more women diagnosed
with diet controlled GDM than insulin for both the user group and nonuser group. Interestingly,
slightly more insulin controlled GDM women were nonusers of the PWP than users of the portal.
This may be due to the medical complexity of insulin management which at times requires more
clinical appointments. Other studies have found that patients with more complex conditions or
multiple co-morbidities have more frequent clinical appointments and less PWP adoption
(Yamin et al., 2011).
Nonusers of the PWP may more often be women with insulin dependent GDM due to
perceived lack of functionality or preferences in the existing PWP. A study by Ronda and
colleagues (2015) found that insulin dependent diabetes patients wanted functionalities in the
PWP such as the ability to add their injected insulin doses to the electronic diary and receive
educational updates. The authors concluded that one uniform PWP may not be suitable for all
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diabetes patients; rather designing separate PWPs for different types of diabetes may be more
successful. A follow-up study of women with GDM could be conducted to determine frequency
of visits with patient’s attitudes or values of the PWP. Furthermore, a future study could
qualitatively explore the perceived barriers of PWP use for patients with insulin controlled
GDM.
It was thought that women with no previous history of GDM would perhaps use the PWP
more than women who had a previous pregnancy with GDM. While more women without a
history of GDM did use the PWP, the difference was not statistically significant.
Limitations
There were several limitations to this study. A common problem with retrospective
designs is the sample size. In an effort to capture enough patients, a power analysis was
conducted. Unfortunately, the numbers fell short to divide the groups into the original three
groupings of nonusers, short-term users, and persistent users resulting in the consolidation of
short-term users and users into one group.
Another limitation of this study was the unmeasured provider and clinic level behaviors
that may have influenced the patient’s use of the PWP. For example, this study did not measure
the provider or RN preferences for the PWP, nor whether or not their preference affected the
patient’s use or nonuse of the PWP. Furthermore, specific clinic practices such as reminder
phone calls for appointments and response time to secure messages were also not captured in this
study. Previous research has suggested that provider and clinician preferences can greatly
influence adoption of patient PWP use (Izarry et al., 2015; Logue & Effken, 2012). Future
studies should capture these variables on this specific population.
This study also is limited to one Internet portal used within one organization therefore;
the results may not be generalizable to other portals, patients, or health care systems (Polit &
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Beck, 2012). This is notable given the wide variation and lack of standardization on the core
elements of each PWP. This particular study encompassed the following PWP features: secure
messaging, appointment reminders, AVS, lab results, flowsheets, and medication refills. Other
studies on PWPs may include other features thus, generalizability is limited. The author
acknowledges that the lack of standard definitions for users and nonusers of PWPs complicates
the overall generalizability of the results. Definitions for users and nonusers were defined for this
study however, vary immensely in the literature.
Finally, the inability to capture time spent in each feature of the PWP was a major
limitation to this study. Number of log-ins or hits within a particular feature of the PWP does
not capture the actual time spent within each feature of the PWP. Many PWP studies exist
whereby usage is measured by the number of log-ins and hits to individual features of the PWP,
but greater clarity is found when both the frequency and duration of PWP use is measured. In
fact, a study by Jones et al. (2015) measured PWP usage by frequency, consistency, intensity,
and duration of PWP use to outline user phenotypes and distinct patterns of use. The authors
claim that amount of use/frequency captures just one domain of effective PWP use (Jones et al.).
The Jones et al. study was the basis for the operational definitions of this study.
Significance
Practice
Nurses play an important role in the promotion and sustainability of PWP use and are
often the gateway to patient enrollment (IOM, 2010; Logue & Effken, 2012; Seckman, 2014).
Nurses are also patient educators and themselves, are one of the largest groups of EHR users
within a healthcare system making it critical that nurses have adequate knowledge of PWP
features and offer insight into future design development (IOM, 2010).
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This study informs nursing practice in several ways. First, it provides insight into the
patient characteristics of users and nonusers of a PWP for GDM self-management. Scant
research exists on this type of technology for GDM management much less the patient
characteristics of these women (Carolan et al., 2015; Osborn, Mayberry, Mulvaney, & Hess,
2010). Understanding the patient differences between users and nonusers of the PWP is key to
overcoming barriers to PWP use and instrumental in the design of future PWP enhancements for
individual preferences. For instance, fulltime employment may be a motivator for PWP use.
Future enhancements to the PWP should engage employed patients in the development and
usability testing prior to implementation. Equally important, is to explore the barriers to PWP
utilization for women who are not employed.
Furthermore, this study highlights some patterns of PWP use. Appointment reminders
and the AVS were the most frequently accessed features of the PWP. Women who frequently
accessed the appointment reminders could potentially respond positively to completing activities
prior to a clinic visit. Examples of such activities include completing health questionnaires,
goals, or administrative forms. Completion of these activities prior to the visit could save time
during the actual appointment.
Women who frequently accessed the AVS may respond to additional factual information
or resources regarding GDM. This may include links to credible websites and/or specific
information embedded in the document. Prior studies suggest that between 70 to 90 percent of
pregnant women are e-health users and 83 percent used the internet to influence a pregnancy
related decision (Lagan, Sinclair, & Kernohan, 2010; Narasimhulu, Karakash, Weedon, &
Minkoff, 2016). As primary educators to patients, nurses have an opportunity to provide
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accurate, credible resources to patients through the AVS, which remains accessible to the patient
throughout the pregnancy.
The PWP may serve as a repository for trusted and credible patient education resources
or website links related to GDM management that are accessible to patients. Specifically, the
PWP could provide nutrition details perhaps including carbohydrate counting guidelines and
links to food/carbohydrate calculators. Exercise guidelines could also be outlined in the PWP.
Previous research indicates that effective GDM management programs and interventions should
include the three categories: (1) self-monitoring of blood glucose levels, (2) dietary and exercise
interventions, and (3) behavioral interventions/counseling (Brankston et al., 2004; Carolan, 2015,
Hopichler & Lechleitner, 2001, Landon et al., 2009; Moses et al., 2009). Certainly, if the intent
of a GDM PWP is to improve maternal, fetal, and neonatal outcomes, the PWP itself should
incorporate these three categories. The results of this PWP study suggest the Carolan (2015)
framework was not used when developing and implementing the PWP however; suggestions on how
incorporate its categories are discussed above.

Another key finding in this study was the consistency of PWP use among users. Users of
the PWP tended to access the PWP over the full third trimester. This is valuable information as
it provides an avenue for ongoing self-management possibilities. Certain strategies could be
delivered at set time periods throughout the third trimester. For instance, currently patients are
provided with a diabetes educational folder at their first visit which is reviewed between the
patient and certified diabetic nurse educator. If PWP users tend to access the PWP throughout the
third trimester, relevant information could be re-sent or reviewed with patients in different time
increments to encourage sustained engagement with the PWP.
It is surprising that secure messaging and medication refills were so underutilized given
most prior research finds these features to be the heavily utilized (Halamka et al., 2008; Silvestre
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et al., 2009; Yamin et al., 2011). As discussed previously, a plausible reason for the lack of
medication refill requests could be the short time period in which the women are taking insulin.
If the initial prescription for insulin was issued in the third trimester and refills were issued for
three or more months, there would be no reason for the patient to request a refill. This
explanation was not validated in this study, but warrants further follow-up.
The infrequent use of secure messaging requires more investigation. Specifically, it is
important that barriers and motivators to secured messaging are further explored. Nurses have
the ability to influence this practice by supporting its use through their own practice and
informing patients of these features. Moreover, nurses can explore other potential barriers to
using any of the PWP features including usability and timeliness of communication and devise
strategies to overcome the barriers.
Theory
The use of the Individual and Family Self-Management Theory (IFSMT) guided this
study (Ryan & Sawin, 2009). This study evaluated the current use of a particular organization’s
PWP for GDM self-management and did not test the IFSMT directly. Part of the reason for
choosing the IFSMT as the guiding framework was its prior use in studies related to health
promotion and more acute conditions (Doering, 2013; NIH reporter). The PWP in this study was
the intervention that had the potential to influence the process of self-management and impact
the distal outcome of glucose levels. Unfortunately, time spent on each feature of the PWP could
not be measured in this study therefore; a connection between PWP use and self-management
behaviors could not be investigated or validated.
This study does address several dimensions of the IFSMT. This study unveils the patient
characteristics of users and nonusers of a PWP for GDM self-management incorporating the
context domain of the IFSMT. White race, private insurance, and fulltime employment may be

69

viewed as protective factors for women with GDM to engage in PWP use. This study informs the
process domain of the IFSMT by introducing a novel technology tool to promote selfmanagement. Patients engaged most in the concepts of knowledge and beliefs by frequently
accessing the AVS and social facilitation by reviewing appointment reminders. While the study
results do not suggest a statistically significant difference in target blood glucose levels (distal
outcome) over the third trimester, they do illustrate continuous improvement over the three
months unlike the nonuser group. This suggests engagement of the self-management process on
some level. Future research should measure the dosage of PWP use in terms of length of time to
determine if patients are utilizing this tool for self-management guidance.
Due to the low overall PWP use, it is worth taking a step back. This study evaluated a
current PWP already in production. It may be advantageous to supplement this study with
usability testing and utilize a more technology based model before future evaluation should be
performed on PWP use for GDM self-management. Usability studies enable PWP designers to
understand the needs of the users and address barriers to improve utilization and effectiveness
Britto, Jimison, Munafo, Wissman, Rogers, et al., 2009). To the best of this author’s knowledge
no usability testing was conducted for the GDM PWP nor was a framework used. The
Technology Acceptance Model (TAM) was created by Davis and explains computer usage
behavior including the cognitive and affective determinants of computer acceptance (Davis,
Bagozzi, & Warshaw, 1989). The TAM postulates that behavioral intention to use computer
technology is influenced by external variables, perceived usefulness, and perceived ease of use.
This model could be the theoretical framework for a future usability study with this PWP for
GDM patients.
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Health Policy
This study could inform improvements in local policy. The healthcare system from
which the study sample was pulled is committed to the use of PWPs for its patients and has
already adopted several practices to increase enrollment. Enrollment with a PWP does not
always equate to ongoing use and additional strategies should be instituted to promote sustained
use of the PWP among its users. Beyond the enrollment information, nurses and other clinicians
should provide patient information on the features of the PWP and how they relate to their
patient/provider interactions. This also means that nurses need to be knowledgeable on the
components of the PWP which may require additional and ongoing training for them as well.
The development and use of PWPs have primarily been promoted for chronic conditions
within the primary care setting since this is where much of the meaningful use financial
incentives reside for providers and healthcare organizations. However, PWP use has been
expanding into certain specialty areas without much modification to its original format. The idea
of “build it and they will come” is not evidenced-based and should not be utilized.
Administrators and clinical staff should explore patient differences and preferences based on
clinical conditions and modify the PWP accordingly. Usability assessments and testing should be
standard when developing and implementing any PWP in any organization. Modifications should
be made based on patient and provider feedback prior to implementation. This study provides
insight into the current use for the GDM population and begins to suggest opportunities for
improvement.
This study also lends itself to a further evaluation of clinician and provider workflow.
Administrators and clinicians alike should appreciate the required changes in outpatient
workflow as compared to in-person visits. Izarry et al. (2015) point to the difficulty of
coordinating PWP management tools with current provider/clinician workflow and priorities
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suggesting that a greater understanding of the adjustments is needed and may require changes in
current roles and responsibilities. A clinician or provider’s work day no longer consists of a
patient schedule with a set number of patients to see in person. It has evolved to be a multifaceted plan of in-person visits, email messages, prescription refills, results review, and other
communication that needs to be coordinated amongst various members of the healthcare team.
Ultimately the adoption of PWPs in any setting, for the population of women with GDM,
or another population, will require time and resources to thoroughly assess the needs of the
patient population, the features needed, the readiness for adoption, usability testing, and ongoing
modifications. This study offers some beginning insights into the characteristics and patterns of
PWP use among current users. Opportunities exist for modifications, enhancements, and
usability testing.
On a more global level, this study contributed to the body of research on PWP use
beyond chronic conditions and primary care. As meaningful use expands it is important to take a
proactive approach to PWP application beyond chronic care and make modifications that are
specific for that patient population.
Research
Since scant research exists on PWPs for GDM management, this study provides just a
glimpse into this subject for a particular healthcare system and offers ample future research
possibilities. It is suggested that this study be replicated in other systems with the same or similar
PWP features and measure patterns of use as defined by frequency, intensity, consistency, and
duration as described by Jones et al. (2015).
Additional research could also explore other outcomes beyond glucose levels. Studies of
PWP use among men and women with diabetes have demonstrated positive effects on diabetes
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distress scores with PWP use (Fonda et al., 2009). For example, and initial study could be
conducted to validate the Diabetes Distress Screening Scale or similar scale on the GDM
population. Then, another study could determine if a relationship exists between PWP use and
diabetes distress. There are additional possibilities to examine medication adherence in this
population of patients. Although insulin use is less frequent than diet management for GDM
control, it is worth investigating whether there is greater medication adherence among women
with GDM who use a PWP. A study by Kim and colleagues (2006) concluded that PWP users
diagnosed with diabetes had greater medication adherence than nonusers of the PWP.however,
given the study is almost a decade old and the additional features of PWPs, this study should be
replicated.
Several opportunities also exist for future qualitative studies. One of great importance is
to explore the barriers of using a PWP for GDM self-management particularly for features such
as secure messaging and medication refills. Beyond the barriers, virtually nothing is known
about what functionality or enhancements users are looking for within a PWP that would
promote GDM self-management or the usability of the current PWP. Other research results have
demonstrated the benefits of early usability testing and patient portal design (Izarry et al., 2015).
Usability testing was not conducted for this organization’s PWP specific to GDM management.
Finally, provider preferences, workflow, and barriers should be explored.
Conclusions
The following conclusion can be made based on the results of this study:
1. Appointment reminders were the most frequently accessed PWP feature.
2. The AVS was the second most commonly accessed PWP feature.
3. Medication refills were not accessed at all by any patient in the study.
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4. PWP users most often accessed the PWP each month in the third trimester.
5. The PWP was most frequently accessed between the hours of 0800-1200.
6. PWP users tended to be employed fulltime.
7. PWP users saw improvements in target blood glucose levels in each of the three
months in the third trimester.
An assumption cannot be made that improvement in target blood glucose levels is
directly correlated with PWP use. Furthermore, healthcare delivery factors such as PWP usability
and provider/clinician endorsement was not measured in this study, but does contribute to
patient’s adoption of the PWP as noted in previous studies (Logue & Effken, 2012; Wald et al.,
2010). It is clear that with the continued CMS and Medicaid incentives for meaningful use,
PWPs will continue to evolve and should be evaluated for their effectiveness. Future research
should aim to determine barriers and facilitators to PWP use for GDM self-management, conduct
usability testing on existing PWPs, and determine which, if any, features of the PWP and length
of time contribute to GDM self-management. . Finally, future studies should not negate
nonusers. It is equally important to understand the self-management activities of this group of
women as they navigate through their pregnancy with GDM. Healthcare systems should not view
PWPs as a panacea, especially for populations of people that may eschew technology for cultural
or other beliefs.
The emergence of health information technology (HIT) and PWPs has created new
opportunities for patient involvement in their healthcare. This technology can only be successful
with the input of patients and the acceptance and adoption of clinicians and providers. It is clear
that future research is needed in order to fully implement a patient-centered PWP that optimizes
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technological capabilities while addressing barriers to its use. Specific user characteristics and
needs should be addressed. Specific features of PWP should be studied and outcomes measured.
Chapter Summary
The findings of the study were discussed and connections to existing literature outlined.
Limitations of the study were clearly reviewed. Significance to practice, theory, policy, and
research were discussed in addition to overall conclusions that can be drawn from this study.
Finally, future research recommendations were suggested.

75

Figure 1. A mapping of study variables using the Individual and
Family Self-Management Theory
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Figure 2. Conceptual Model using the Individual and Family Self-Management Theory

Figure 2. Conceptual model for study adapted from the IFSMT of Ryan and Sawin (2009).
Variables of the study are listed according to the IFSMT dimensions: Context, Process, and
Distal Outcome.
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Table 1
Context Dimension Variables
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Table 2
Process/Outcome Dimension Variables
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Table 3.
Studies of the Impact of Patient Web Portals on Diabetes Patient Outcomes

Author/year

Study
design/level
of evidence*

Duration
of Study

Subjects

Intervention/Control
groups (if applicable)

Measures

Outcomes/Results

Fonda et al./
2009

RCT

12 months

N= 102
N= 52 intervention,
N=52 control
Type 1 and Type 2
DM

Intervention: Internetbased care management
(MyCare Team website,
glucose and BP readers)

Diabetes distress

Decreases in HbA1c and diabetes
distress based on level of usage.

Level II

HbA1c levels
Distress scores lower among users
than nonusers

Control: Usual care
USA
Grant et al.
/2008

Cluster
randomized
control trial

12 months

N= 126
intervention group
N= 118 control
group
Type 2 DM
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Level II

11 primary care
clinics in
Massachusetts

Holbrook et
al./ 2009

RCT

5 months

N=511
Type 2 DM

Level II
Primary care
setting
Canada

Intervention: access to
DM specific application
with medication
management, view of
current treatment, BP, &
preventive care

HbA1c levels, BP,
lipid levels

Decreased rate of primary care visits
Decrease in HbA1c level after 1 yr
(0.16% vs. 0.26%, p=0.62)
Slight improvement in BP & lipids
after 1 yr (not significant)

Control: usual care
Medication adjustment for
hyperglycemia (29% vs. 15%, p=0.1).

Intervention: web-based
color-coded diabetes
tracker and messaging

Continuity of care
Quality of life
satisfaction

Control: Usual care
Clinical and process
composite scores

Medication adjustment for
hyperlipidemia (11% vs. 0%, p=0.03)
Process composite score significantly
better in intervention vs. control
(difference 1.27, p<0.001)
Intervention group vs. control had
improvement (difference 19.1%,
p<0.001)
Clinical composite score significantly
better in intervention vs. control (0.59,
p=0.02)
Intervention group reported greater
satisfaction with diabetes care

Table 3.
Studies of the Impact of Patient Web Portals on Diabetes Patient Outcomes
Author/year

Study
design/level
of evidence*

Duration
of Study

Subjects

Intervention/Control
groups (if applicable)

Measures

Outcomes/Results

Kim et al./
2006

Pre-post

3 months

N=45
Type 2 DM

Intervention: short
message by cell phone
and internet web portal

HbA1c levels, 30
min. exercise
(days/week),
adherence to
medication
(days/week), & foot
care (days/week)

HbA1c difference -1.1% + 2.1
(p<0.006)
Exercise difference: 0.9 + 2.0
days/week (p<0.036)
Medication adherence difference: 1.1
+ 1.9 days/week (p<0.032)
Foot care difference: 1.1 + 2.2
days/week (p<0.030)

Level IV
Korea

No control

McCarrier et
al./2009

Pilot, RCT
Level II

12 months
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McMahon et
al./ 2005

RCT
Level II

12 months

N= 77
29-49 years old
Type 1 diabetes
Last HgA1c level
>7.0%

Intervention: usual care
plus the nursepractitioner-aided Webbased case management
program

Seattle, WA

Control: usual clinic care

N=104

Intervention: diabetes
education class + webbased care management
(glucose, BP monitoring
devices, & website)

Type 1 and Type 2
DM
USA

Control: usual care of
diabetes education class

HgA1c
Self-efficacy

intervention group had decrease in
HgA1C test values of 0.37%, control
group had slight increase of 0.11%.
(difference of -0.48% was not
significant)
beneficial treatment effect on selfefficacy

HbA1c levels
BP
HDL
LDL
Triglycerides

HbA1c levels -1.2 in control vs. -1.6%
in intervention group (p<0.05)
BP levels significantly decreased in
intervention group (-10 + 17) vs.
control (-7 +21 mmHg) p<0.01
LDL change- not significant, HDL
levels increased in intervention group
(3 + 6 mg/dl) vs. control (1 +6 mg/dl)
p<0.05. Triglycerides significantly
decreased in intervention group (-38 +
99 mg/dl) vs. control (-2 + 60 mg/dl)
p<0.01

Table 3.
Studies of the Impact of Patient Web Portals on Diabetes Patient Outcomes
Author/year

Study
design/level
of evidence*

Duration
of Study

Subjects

Intervention/Control
groups (if applicable)

Measures

Outcomes/Results

Noel et al.
/2004

RCT

12 months

N=104
Single co-morbid
diagnoses: heart
failure, chronic
lung disease,
diabetes

Intervention: home
telehealth (electronic
monitoring and alert
system) + nurse case
management

HbA1c levels

HbA1c levels: +0.8% in control vs. 1% in intervention (p<0.01)
Cognitive status: 19.4 in control vs.
20.0 in intervention (p<0.01)
Urgent visits: +5 in control vs. -83 in
intervention group (p<0.05)
Functional level, pat. satisfaction, selfrate health, & total visits- not
significant

Level II

USA

Osborn et
al./2013

Mixed
methods
study, crosssectional
design

Not
defined

75 adults with
Type 2 DM
receiving
medications

Control: Usual home
health care + nurse case
management

Focus groups, surveys,
and medical chart review

Quality of Life
(cognitive status,
functional level,
patient satisfaction,
self-rated health)
Urgent & total visits

Use of portal
Methods portal users
use to manage their
medication

82

English speaking
Level IV

Ideas to improve
functionality of portal

Recruited from
VUMC primary
care clinics in
Nashville, TN

Osborn et
al./2010

Systematic
review

Studies
published
from1/200
0-2010

26 articles
reviewed
Type 1 or Type 2
diabetes

Portal users more likely to be White,
have higher incomes, & have private
insurance
More frequent use of portal was
associated with better A1C (Spearman
rho= - 0.30, p=.02)
Suggestions to improve functionalitylink to pharmacy, deliver med
information in a user-friendly format

Impact of diabetes
interventions using PWP
on improving self-care
behaviors, glycemic
control, and health
outcomes

Self-care behaviors,
glycemic control,
health outcomes

PWP-delivered interventions:
Enhance patient-provider
communication, expand access to
health information, improve disease
management and patient outcomes

Table 3.
Studies of the Impact of Patient Web Portals on Diabetes Patient Outcomes
Author/year

Study
design/level
of evidence*

Duration
of Study

Subjects

Intervention/Control
groups (if applicable)

Measures

Outcomes/Results

Ralston et
al./2009

Pilot RCT

12 months

N= 83
18 to 75 years old
with type 2
diabetes

HgA1c
BP
Total cholesterol

HgA1c levels declined by 0.7% (95%
CI 0.2−1.3) on average among
intervention patients compared with
usual-care patients.

HgA1c in the prior
12 months was
≥7%

Intervention: access to
electronic medical
records, secure e-mail
with providers, feedback
on blood glucose
readings, education, and
an interactive online
diary

Seattle, WA

Control: usual care

All patients with
Type 1 or Type 2
DM and enrolled in
a provider-centered
decision support
tool included

N/A

Level II

Shaw &
Ferranti/2011

Crosssectional
secondary
analysis

5 months

83

Level IV

Smith et al./
2004

Pre-post test

9 months

Level IV

From DUMC
Portal users n=
5,937, nonusers n=
14,085
N=16
Type 1 and Type 2
DM
USA

Systolic blood pressure, diastolic
blood pressure, total cholesterol
levels, and use of in-person health
care services did not differ between
the two groups.
% of diabetes patients
that use a portal

29.7% of patients with diabetes use
the portal

HbA1c levels
Lipid levels

Portal use was a significant predictor
of HbA1c (p< .0001)
Portal use not a significant predictor
of LDL and total cholesterol levels

Intervention:
MyCareTeam programweb-based diabetes
management program.
Pts entered blood
glucose levels, exercise
log, and got messages
No control

HbA1c levels, BP,
HDL, LDL,
triglycerides

HbA1c levels -2.2% (p<0.0001)
reduction in heavy users
BP, HDL, LDL, & triglycerides- not
significant

Abbreviations Used in Evidence Table
&: and BMI: body mass index BP: blood pressure btwn: between difft: different DM: diabetes mellitus DUMC: Duke University Medical Center ER: emergency room
govt: government HbA1c: hemoglobin A1c HDL: high-density lipoprotein LDL: low-density lipoprotein mg/dl: milligrams per deciliter
MHAV: MyHealthAtVanderbilt mmHg: millimeters of mercury min: minutes N: number PCP: primary care provider pts: patients PWP- patient web portal RCT: randomized
control trial SES: socioeconomic status vs: versus VUMC: Vanderbilt University Medical Center yr: year

Table 4.
Conceptual and Operational Definitions of Study Variable
Variable
CHARACTERISTICS
Age

Conceptual Definition

Operational Definition

the number of years since
a person's date of birth.

Self-reported number
of years since the
person’s date of birth.
Reported in a whole
number over the age
17.
Self-reported race
according to the choices
outlined by the Office of
Management and
Budget with the U.S.
government

18-100

Self-reported ethnicity
according to the choices
outlines by the Office of
Management and
Budget with the U.S.
government
Self-reported marital
status according to the
EHR provided choices

Hispanic/Latino
NonHispanic Latino
Patient refused
Unknown

Race

Category of humankind
that share distinctive
physical traits (MerriamWebster dictionary)

Ethnicity

Ethnic quality or affiliation
(Merriam-Webster
dictionary)

Marital Status

The condition of being
married or unmarried

Insurance

Private insurance is
coverage obtained
through an employer,
union, or individual
purchase. Public insurance
is Medicaid, Medicare,
other governmentsponsored programs, or a
military health plan
(TRICARE, VA, or CHAMPVA). Adults covered by
both private and public

Scanned health
insurance card
information at time of
first visit to the
diabetes in pregnancy
clinic
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Response Type

American
Indian/Alaska Native
Asian
Black or African
American
Native Hawaiian or
Pacific Islander
White/Caucasian
Other
Unknown
Patient refused

Divorced
Legally separated
Married
Significant Other
Single
Widowed
Unknown
Will then categorize
to:
Private
Public
Uninsured
Nothing on file

Employment

insurance were
considered to have
private insurance. Persons
without private or public
insurance and those with
only Indian Health Service
coverage or only a private
plan that paid for one
type of service such as
accidents or dental care
are considered uninsured
(CDC, 2012)
Work for another in
return for financial or
other compensation.

BMI

Measure of body fat
based on height and
weight in the adult
male/female

Type of GDM

Blood sugars are
maintained through diet
alone or in combination
with insulin

Preg. with GDM

Any prior pregnancies
with a diagnosis of GDM

PWP FEATURES
Patient/Provider
messaging

Flowsheets/Blood sugar
log

Exchange secure e-mail
with their health care
providers via the
patient portal
(HealthIT.gov)
Enter/review blood
sugar numbers in a
secure flowsheet via

Self-reported
employment status
according to the EHR
choices of yes, or no.
Weight in kilograms
divided by the square of
height in meters (CDC).
This is a calculation in
the EHR based on data
entered for weight and
height.
Documentation within
the EHR of diet
controlled GDM or
insulin. If at any point
the patient was started
on insulin, code for
insulin.
Any prior pregnancies
with a diagnosis of GDM
as noted within the EHR
and validated by
patient’s report. With
or without live birth.

Fulltime
Part-time
Self-employed
Not employed
1-100

Measured by the
number of times the
patient sent a secure
message to the GDM
provider (Nurse or
MFM) in the third
trimester.
Measured by number of
times the patient enters
or reviews data in blood

Whole number
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Diet controlled
Insulin

Yes
No

Whole number

After visit
summary/instructions

Labs

the patient portal.
Patient and provider as
access to this data.
Summary and/or
instructions regarding
the clinic visit for a
specific date. Sent via
secure messaging via
patient portal.
Results of any
diagnostic test that can
be reviewed via the
patient portal

Appointment reminders

A scheduled reminder
via the patient portal of
an upcoming
appointment for the
patient.

Medication refills

Medication refill
message sent by patient
to provider via secure
messaging.

OUTCOME
Target blood sugars

PWP USE
PWP frequency of use

PWP pattern of use

Percentage of blood
sugars that are within
the target range for
adequate glycemic
control for GDM

sugar log flowsheets
during the third
trimester.
Measured by the
number of times the
patient selects the after
visit summaries related
to GDM visits during the
third trimester.
Number of times
Hemoglobin A1c levels
and Glucose tolerance
tests are reviewed via
patient portal during
the third trimester of
pregnancy.
The number of times
the appointment
reminder for GDM visits
were reviewed by the
patient during the third
trimester of pregnancy.
Insulin medication refill
requests sent to GDM
provider via secure
messaging during the
third trimester of
pregnancy.
Percentage of reported
blood sugars per
subject that is less than
125 mg/dL each month

number of “hits” or
times the patient
accesses a feature of
the PWP.

Number of times a
subject logs-in or
accesses a certain
feature of the PWP
related to GDM during
the third trimester
Utilization of features of
 PWP features
the PWP over time.
accessed
Examples: clustered
 number of hits
activity to first month
to each feature
then stopped using or
 Consistency
only used one feature
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Whole number

Whole number

Whole number

Whole number

Percentage per month
and then for entire
third trimester

Whole number

Based on categories of
users
List of what features
used over the study
period.

of the PWP entire time

Hit day= any
day the patient
accessed the PWP in
the third trimester
regardless of the
number of times
accessed that day or
features accessed.
Hit month =
captured any individual
month where the
patient accessed any
feature of the PWP at
least once.
 Time of day

Reported in mean

Reported in mean

Reported in 4 hour
increments

87

References
Abraham, K & Wilk, N. (2014). Living with gestational diabetes in a rural community. MCN.
American Journal of Maternal Child Nursing, 39(4), 239-245. doi:
10.1097/NMC.0000000000000047
Ahern, D.K., Woods, S.S., Lightowler, M.C., Finley, S.W., & Houston, T.K. (2011). Promise
of and potential for patient-facing technologies to enable meaningful use. American
Journal of Preventive Medicine, 40(5), 162-172. doi: 10.1016/j.amepre.2011.01.005
Alwan, N., Tuffnell, D.J., & West, J. (2009). Treatments for gestational diabetes. Cochrane
Database Systematic Review, 8 (3):CD003395. Retrieved from
https://www.ncbi.nlm.nih.gov/pubmed/19588341.
American College of Obstetrics and Gynecology (ACOG) (2004). Diabetes and pregnancy.
ACOG Technical Bulletin #200. Washington, DC.
American College of Obstetrics and Gynecology (ACOG). (2013). Committee on Practice
Bulletins. Obstetrics. Practice Bulletin No. 137: gestational diabetes mellitus. Obstetrics
and Gynecology, 122:406–416.
American Diabetes Association (1997). Report of the expert committee on the diagnosis and
classification of diabetes mellitus. Diabetes Care, 20, 1183-97. Retrieved from
https://www.ncbi.nlm.nih.gov/pubmed/9203460.
American Diabetes Association (2008). Nutrition Recommendations and Interventions for
Diabetes. Diabetes Care, 31, 61-78. http://dx.doi.org/10.2337/dc08-S061
American Diabetes Association (2013). Standards of Medical Care in Diabetes—2013. Diabetes
Care, 36, S11-S66. doi: 10.2337/dc13-S011

88

American Diabetes Association. (2016). Guidelines: diabetes in pregnancy GDM. Retrieved
from http://www.ndei.org/ADA-diabetes-management-guidelines-diabetes-in-pregnancy
GDM.aspx.html
American Diabetes Association (2016). What is gestational diabetes? Retrieved from
http://www.diabetes.org/diabetes-basics/gestational/what-is-gestational-diabetes.html
American Nurses Association. (2010). Nursing’s social policy statement: The essence of the
profession. Silver Springs, MA: American Nurses Association.
Ancker, J.S., Barron, Y., Rockoff, M.L., Hauser, D., Pichardo, M., Szerencsy, A., & Calman, N.
(2011). Use of an electronic patient portal among disadvantaged populations. Journal of
General Internal Medicine, 26(10), 1117-1123. doi: 10.1007/s11606-011-1749
Balsells, M., Garcia-Patterson, A., Sol al Roque, M., & Corcoy, R . (2015). Glibenclamide,
metformin, and insulin for the treatment of gestational diabetes: A systematic review and
meta-analysis. British Journal of Medicine, 350, 102. doi: 10.1136/bmj.h102
Becerra, J.E., Khoury, M.J., Cordero, J.F., & Erickson, J.D.(1990). Diabetes mellitus during
pregnancy and the risks for specific birth defects: a population-based case-control study.
Pediatrics. 85(1),1-9. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/2404255
Bellamy L., Casas, J.P., Hingorani, A.D., Williams, D. (2009). Type 2 diabetes mellitus after
gestational diabetes: A systematic review and meta-analysis. Lancet, 373:1773–1779.
doi: 10.1016/S0140-6736(09)60731-5.
Benedetti, T.J. (1991). Dystocia: Causes, consequences, correct response. Contemporary
Ob/GYN, 36, 37-48.

89

Blank, A., & Graves, G.D. (1995). Effects of gestational diabetes on perinatal morbidity
reassessed. Report of the International Workshop on Adverse Perinatal Outcomes of
Gestational Diabetes Mellitus. Diabetes Care, 18, 127-129.
Brankston, G. N., Mitchell, B. F., Ryan, E. A., & Okun, N. B. (2004).Resistance exercise
decreases the need for insulin in overweight women with gestational diabetes mellitus.
American Journal of Obstetrics and Gynecology, 190(1), 188—193.
Britto, M.T., Jimison, H.B., Munafo, J.K., Wissman, J., Rogers, M.L., & Hersh, W. (2009).
Usability testing finds problems for novice users of pediatric portals. Journal of the
American Medical Informatics Association, 16(5), 660-669.
https://doi.org/10.1177/1541931214581132
Bung, P., Artal, R., Khodiguin, N., & Kjos, S. (1991). Exercise in Gestational Diabetes: An
Optional therapeutic approach. Diabetes, 2, 182-185. Retrieved from
https://www.ncbi.nlm.nih.gov/pubmed/1748256
Carolan, M., Steele, C., & Margetts, H. (2010). Attitudes towards gestational diabetes among a
multi-ethnic cohort in Australia. Journal of Clinical Nursing, 19, 2446-2453. Retrieved
from https://core.ac.uk/download/pdf/10834391.pdf
Carolan, M, Gill, G.K., & Steele, C. (2012). Women’s experiences of factors that facilitate or
inhibit gestational diabetes self -management. BMC Pregnancy and Childbirth, 12 (99).
doi:10.1186/14712393-12-99
Carolan, M.C. (2015). Educational and intervention programmes for gestational diabetes
mellitus (GDM) management: An integrative review. Collegian.
doi:10.1016/j.colegn.2015.01.001

90

Carolan, M., Steele, C., & Krenzin, G. (2015). Development and initial testing of a GDM
information website for multi-ethnic women with GDM. BMC Pregnancy &
Childbirth, 15(145), 1-9. doi:10.1186/s12884-015-0578-0
Carr, D.B. & Gabbe, S. (1998). Gestational diabetes: Detection, management, and implications.
Clinical Diabetes, 16(1), 1-17. Retrieved from
http://journal.diabetes.org/clinicaldiabetes/v16n1J-F98/pg4.htm
Carr, D.B., Utzschneider, K.M., Hull, R.L., Tong, J., Wallace, T.M., Kodama, K., Shofer, J.B.,…
Kahn, S.E. (2006). Gestational diabetes mellitus increases the risk of cardiovascular
disease in women with a family history of type 2 diabetes. Diabetes Care, 29, 2078
2083.doi: 10.2337/dc05-2482
Centers for Medicare and Medicaid Services (CMS). (2016). 2016 Program requirements.
Retrieved from https://www.cms.gov/Regulations-and
Guidance/Legislation/EHRIncentivePrograms/2016ProgramRequirements.html
Cheung, N.W. (2009). The management of gestational diabetes. Vascular Health and Risk
Management,5, 153-164.
Corbin, J.M., & Strauss, A. (1988). Unending work and care: Managing chronic illness at home.
San Francisco: Jossey-Bass.
Courtenay, W. (2009). Theorizing masculinity and men’s health. In A. Broom & P. Tovey
(Eds.), Men’s health: Body, identity and social context (pp. 9-32). London, UK: Wiley
Blackwell.
Coustan, D.R. (2007). Pharmacological management of gestational diabetes: An overview.
Diabetes Care,30, 206-208. doi: 10.2337/dc07-s217
Coustan, D.R. (1995). Gestational diabetes. Diabetes in America, 2nd edition. p. 703-717.

91

Crowther, C.A., Hiller, J.E., Moss, J.R., McPhee, A.J., Jeffries, W.S., & Robinson, J.S. (2005).
Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. Australian
Carbohydrate Intolerance Study in Pregnancy Women (ACHOIS) Trial Group. New
England Journal of Medicine, 352, 2477-2486. doi: 10.1056/NEJMoa042973
Davis, F.D., Bagozzi, R.P., & Warshaw, P.R. (1989). User acceptance pf computer technology:
A comparison of two theoretical models. Management Science, 35(8), 982-1002.
http://dx.doi.org/10.1287/mnsc.35.8.982
De Luca, A.K., Nakazawa, C.Y., Azevedo, B.C., Rudge, M.V., De Araujo, R.A., & Calderon,
I.M. (2009). Influence of glycemic control on fetal lung maturity in gestations affected by
diabetes or mild hyperglycemia. Acta Obstetricia Gynecologica Scandinavica,88 (9),
1036-1040. .doi: 10.1080/00016340903118018.
DeSisto, C.L., Kim, S.Y., & Sharma, A.J. (2014). Prevalence estimates of gestational
diabetes mellitus in the United States, pregnancy risk assessment monitoring system.
Preventing Chronic Disease,11: E104. doi: 10.5888/pcd11.130415.
De Veciana, M., Major, C.A., Morgan, M.A., Asrat, T., Toohey, J.S., Lien, J.M., & Evans,
A.T. (1995). Postprandial versus preprandial blood glucose monitoring in women with
gestational diabetes mellitus requiring insulin therapy. New England Journal of Medicine,
333, 1237-1241. doi:10.1056/NEJM199511093331901
Devsam, B.U., Bogossian, F.E., & Peacock, A.S. (2013). An interpretive review of women’s
experiences of gestational diabetes mellitus: proposing a framework to enhance
midwifery assessment. Women Birth, 26(2), e69-76. doi: 10.1016/j.wombi.2012.12.003

92

Doering, J. (2013). The Physical and Social Environment of Sleep in Socioeconomically
Disadvantaged Postpartum Women. Journal of Obstetric, Gynecologic, and Neonatal
Nursing : JOGNN / NAACOG, 42(1), E33–E43. http://doi.org/10.1111/j.1552
6909.2012.01421.
Dunne, F., Brydon, P., Smith, K., & Gee, H. (2003). Pregnancy in women with Type 2 diabetes:
12 years outcome data 1990-2002. Diabetes Medicine, 20(9), 734-738.
doi:10.1046/j.1464-5491.2003.01017.x
Emont, S. (2011). Measuring the impact of patient portals: What the literature tells us. Retrieved
from California Healthcare Foundation website
http://www.chcf.org/~/media/MEDIA%20LIBRARY%20Files/PDF/M/PDF%20Measur
ngImpactP atientPortals.pdf
Eriksson, J.G., Forsen, T.J., Osmond, C., & Barker, D.J.(2003). Pathways of infant and
childhood growth that lead to type 2 diabetes. Diabetes Care, 26(11), 3006-3010.
https://doi.org/10.2337/diacare.26.11.3006
Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007). G*Power 3: A flexible statistical
power analysis program for the social, behavioral, and biomedical sciences. Behavior
Research Methods, 39, 175-191. doi:10.3758/BF03193146
Ferrara,A., Kahn, H., Quesenberry, C., Riley, C., & Hedderson, M. (2004). An increase in the
incidence of gestational diabetes mellitus: Northern California, 1991-2000. Obstetrics &
Gynecology, 103(3), 526-533. doi: 10.1097/01.AOG.0000113623.18286.20
Ferrara, A., Hedderson, M.M., Ching, J., Kim, C., Peng, T., & Crites, Y.M. (2012). Referral to
telephonic nurse management improves outcomes in women with gestational diabetes.

93

American Journal of Obstetrics and Gynecology, 206(6), e1-5. doi:
http://dx.doi.org/10.1016/j.ajog.2012.04.019
Fleming, N., Cullen, D., & Luna, G. (2015). An evaluation of patient web portal engagement: An
exploratory study of patients with hypertension and diabetes. Online Journal of Nursing
Informatics, 19(3). Retrieved from http://www.himss.org/ojni
Fonda, S.J., McMahon, G.T., Gomes, H.E., Hiskson, S, & Conlin, P.R. (2009). Changes in
diabetes distress related to participation in an internet-based diabetes care management
program and glycemic control. Journal of Diabetes Science Technology, 3, 117-124. doi:
10.1177/193229680900300113.
Gabbe, S.G. (1993). Identifying patients with GDM. OB/Gyn Clinical Alert.
Gethun, D., Nath, C., Ananth, C., Chavez, M., & Smulian, J. (2008). Gestational diabetes
in the United States: Temporal trends 1989-2004. American Journal of Obstetrics &
Gynecology, 198, 525. E1-5. https://doi.org/10.1016/j.ajog.2007.11.017.
Gibson, B. (2014). Personal health records (PHRs). In R. Nelson, & N. Staggers (1st Eds.),
Health informatics: An interprofessional approach (pp. 244-256).
Glasgow, R.E., & Anderson, R.M. (1999). In diabetes care, moving from compliance to
adherence is not enough: Something entirely different is needed. Diabetes Care, 22(12),
2090-2092. https://doi.org/10.2337/diacare.22.12.2090
Glastras, S., & Fulcher, G. (2012). Guidelines for the managementof gestational diabetes in
pregnancy. Clinical Practice, 9(2),161-170.
Grant, R.W., Wald, J.S., Schnipper, J.L, Gandhi, T.K., Poon, E.G., Orav,… Middleton, A.
(2008). Practice-linked online personal health records for type 2 diabetes mellitus: A
randomized controlled trial. Archives of Internal Medicine, 168(16), 1776-82.

94

Grey, M., Knafl, K., & McCorkle, R.(2006). A framework for the study of self and family
management of chronic conditions. Nursing Outlook, 54(5), 278–286.
https://doi.org/10.1016/j.outlook.2006.06.004
Gunderson, E.P. (1997). Intensive nutrition therapy for gestational diabetes. Diabetes Care, 20,
221-226. doi:10.1007/s11892-004-0041-5
HAPO Study Cooperative Research Group. (2008). Hyperglycemia and adverse pregnancy
outcomes. New England Journal of Medicine, 358, 1991-2002.
doi:10.1056/NEJMoa0707943
Halamka, J.D., Mandl, K.D., & Tang, P.C. (2008). Early experiences with personal health
records. Journal of the American Medical Informatics Association, 15(1), 1-7.
https://dx.doi.org/10.1197%2Fjamia.M2562
Health IT.gov. (2013). Meaningful Use. Retrieved from
http://www.healthit.gov/providersprofessionals/achieve-meaningful-use/core-measures
2/patient-ability-electronicallyview-download-transmit-vdt-health-information
Hibbard, J., & Greene, J. (2013). What the evidence shows about patient activation: Better health
outcomes and care experiences; fewer data on costs. Health Affairs, 32(2), 207-214. doi:
10.1377/hlthaff.2012.1061
Healthcare Information and Management Systems Society (HIMSS). (2016). Electronic health
record. Retrieved from http://www.himss.org/library/ehr/
Hoffman, L., Nolan, C., Wilson, J.D., Oats, J.J., & Simmons, D. (1998). Gestational
diabetes mellitus management guidelines. Medical Journal of Australia, 169, 93-97.
https://www.ncbi.nlm.nih.gov/pubmed/9700346

95

Hoppichler, F., & Lechleitner, M. (2001). Counseling programs and the outcome of gestational
diabetes in Austrian and Mediterranean Turkish women. Patient Education and
Counseling, 45(4),271-274. https://www.ncbi.nlm.nih.gov/pubmed/11755772
Hui, A.L., Sevenhuysen, G., Harvey, D., Salamon, E. (2014). Stress and anxiety in women with
gestational diabetes during dietary management. The Diabetes Educator,40, 668-677.
https://doi.org/10.1177/0145721714535991
IBM Corp. Released 2015. IBM SPSS Statistics for Windows, Version 23. Armonk, NY: IBM
Corp.
Institute of Medicine (2002). Dietary Reference Intakes: Energy, Carbohydrate, Fiber, Fat, Fatty
Acids, Cholesterol, Protein, and Amino Acids. Washington, DC, National Academies
Press.
Irizarry, T., DeVito-Dabbs, A., & Curran, C.R. (2015). Patient portals and patient engagement:
A state of the science review. Journal of Medical Internet Research, 17(6), e148.
doi.10.2196/jmir.4255
Jackson, C.L., Boren, S., Brancati, F.L., Batts-Turner, M., & Gary, T.L. (2006). A systematic
review of interactive computer- assisted technology in diabetes care. Journal of General
InternalMedicine,21(2),105-110.https://dx.doi.org/10.1111%2Fj.1525
1497.2005.00310.x
Jones, J., Weiner, J., Shah, N., & Stewart, W. (2015). The wired patient: Patterns of electronic
patient portal use among patients with cardiac disease or diabetes. Journal of Medical
Internet Research,17(2):e42. doi:10.2196/jmir3157.
Jovanovic, L., & Peterson, C.M. (1985). Screening for gestational diabetes: Optimum timing and
criteria for retesting. Diabetes, 4, 21-23. https://www.ncbi.nlm.nih.gov/pubmed/3996766

96

Jovanovic-Peterson,L., & Peterson,C. (1990). Dietary manipulation as a primary treatment
strategy for pregnancies complicated by diabetes. Journal of the American College of
Nutrition,9(4), 320-325. https://www.ncbi.nlm.nih.gov/pubmed/2212389
Kaptein, S., Evans, M., McTavish, S., Banerjee, A.T., Feig, D.S., Lowe, J., & Lipscombe,L.L.
(2014). The subjective impact of a diagnosis of gestational diabetes among
ethnically diverse pregnant women: A qualitative study. Canadian Journal of
Diabetes, 1-20. https://doi.org/10.1016/j.jcjd.2014.09.005
Kc, K., Shakya, S., & Zhang, H. (2015). Gestational diabetes mellitus and macrosomia: A
literature review. Annals of Nutrition and Metabolism, 6, 14-20. doi: 10.1159/000371628.
Kim, H.S., Kim, N.C., & Ahn, S.H. (2006). Impact of a nurse short message service intervention
for patients with diabetes. Journal of Nursing Care Quality, 21, 266-271.

Kim C., Newton, K.M., & Knopp, R.H. (2002). Gestational diabetes and the incidence of type
2 diabetes: A systematic review. Diabetes Care, 25(10), 1862-1868.
https://doi.org/10.2337/diacare.25.10.1862
Kim, S. Y., England, L., Wilson, H. G., Bish, C., Satten, G. A., & Dietz, P. (2010).
Percentage of gestational diabetes mellitus attributable to overweight and obesity.
American Journal of Public Health, 100(6), 1047-1052. doi:10.2105/AJPH.2009.172890
Kruse, C. S., Bolton, K., & Freriks, G. (2015). The effect of patient portals on quality outcomes
and its implications to meaningful use: A systematic review. Journal of Medical Internet
Research, 17(2), e44. https://dx.doi.org/10.2196%2Fjmir.3171
Kuhl, C. & Holst, J.J. (1976). Plasma glucagon and insulin: Glucagon ratio in gestational
diabetes. Diabetes,25, 16. https://doi.org/10.2337/diab.25.1.16

97

Kwon, H.S., Cho, J.H., Kim, H.S., Song, B.R., Ko, S.H., Lee, J.M., Kim, S.R., … Yoon, K.H.
(2004). Establishment of blood glucose monitoring system using the internet. Diabetes
Care,27(2), 478-483. https://doi.org/10.2337/diacare.27.2.478
Lagan, B., Sinclair, M., & Kernohan,W. (2010). Internet use in pregnancy informs women’s
decision making: A web-based survey. Birth, 37(2), 106-115.doi:10.1111/j.1523
536X.2010.00390.x
Lam, R., Lin, V., Senelick, W., Tran, H-P., Moore, A.A., & Koretz, B. (2013). Older adult
consumers’ attitudes and preferences on electronic patient-physician messaging.
American

Journal

of

Managed

Care,19(10),eSP7-eS11

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4056337/
Landon, M. B., Spong, C. Y., Thom, E., Carpenter, M. W., Ramin, S.M., Casey, B., Wapner,
R…Anderson, G. (2009). A multicenter, randomized trial of treatment for mild
gestational diabetes. New England

Journal

of

Medicine,

361(14),

1339-1348.

https://dx.doi.org/10.1056%2FNEJMoa0902430
Landy, H.J., Gomez-Marin, O., & O’Sullivan, M.J. (1996). Diagnosing gestational diabetes
mellitus: Use of a glucose screen without administering the glucose tolerance test.
Obstetrics and Gynecology,87, 395-400.
Langer, O., Conway, D.L., Berkus, M.D., Xenakis, E.M.-J., & Gonzalez, O. (2000). A
comparison of glyburide and insulin in women with gestational diabetes mellitus. New
England Journal of Medicine, 343, 1134-1138.
Langer, O., Yogev, Y., Xenakis, E., & Brustman, L. (2005). Overweight and obese in
gestational diabetes: the impact on pregnancy outcome. American Journal of
Obstetrics and Gynecology, 192(6),1768-1776. https://doi.org/10.1016/j.ajog.2004.12.049

98

Laz, T., & Berenson. (2012). Racial and ethnic disparities in internet use for seeking health
information among young women. Journal of Health Communication, 250-260.
Logue, M.D., & Effken, J. (2012). Modeling factors that influence personal health records
adoption. Computers, Informatics, Nursing, 30(7), 354-362.
https://doi.org/10.1097/NXN.0b013e3182510717
Lokey, E.A., Tran, Z.V., Wells, C.L., Myers, B.C., & Tran, A.C. (1991). Effect of physical
exercise on pregnancy outcomes: a meta-analytic review. Medicine and Science in Sports
and Exercise, 23, 1234-1239.Retrieved from http://journals.lww.com/acsm
msse/pages/articleviewer.aspx?year=1991&issue=11000&article=00006&type=abstract
Lorig, K., & Holman, H. (2003). Self-management education: History, definition, outcome and
mechanisms. Annals of Behavioral Medicine, 26(1), 1–7. doi:
10.1207/S15324796ABM2601_01
Lorig, K.R., Sobel, D.S., Ritter, P.L., Laurent, D., & Hobbs, M. (2001). Effect of a selfmanagement program on patient with chronic disease. Effective Clinical Practice,4(6),
256-262.
Major, C.A., de Veciana, M., Morgan, M.A., & Henry, J.A. (1993). Glucose monitoring in
gestational diabetics requiring insulin: Preprandial or postprandial? American Journal of
Obstetrics and Gynecology,168, 406-406. doi: 10.1056/NEJM199511093331901
Mayberry, L.S., Kripalani, S., Rothman, R.L., & Osborn, C.Y. (2011). Bridging the digital divide
in diabetes: Family support and implications for health literacy. Diabetes Technology and
Therapeutics, 13(10), 1005-1012. doi: 10.1089/dia.2011.0055
McCarrier, K.P., Ralston, J.D., Hirsch, I.B., Lewis, G., Martin, D.P., Zimmerman, F.J., &
Goldberg, H.I. (2009). Web-based collaborative care for type 1 diabetes: A pilot
99

randomized trial. Diabetes Technology & Therapeutics, 11(4), 211-217.
doi:10.1089/dia.2008.0063.
McKinney, P.A., Parslow, R., Gurney, K.A., Law, G.R., Bodansky, H.J., & Williams, R.
(1999). Perinatal and neonatal determinants of childhood type 1 diabetes. A case-control
study in Yorkshire, U.K. Diabetes Care, 22(6), 928-32.
https://doi.org/10.2337/diacare.22.6.928
McFarland, M.B., Trylovich, C.G., & Langer, O. (1998). Anthropometric differences in
macrosomic infants of diabetic and nondiabetic mothers. Journal of Maternal Fetal
Medicine, 7, 292-295. doi:10.1002/(SICI)1520-6661(199811/12)7
McMahon, G.T., Gomes, H.E., Hickson Hohne, S., Hu, T., Levine, B.A., & Conlin, P.R. (2005).
Web-based care management in patients with poorly controlled diabetes. Diabetes Care,
28, 1624-1629. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1262644/
Meigs, J.B., Cagliero, E., Dubey, A., Murphy-Sheehy, P., Gildesgame, C., Chueh,
H.,Barry, M..J…Nathan,D.. (2003). A controlled trial of web-based diabetes disease
management: The MGH diabetes primary care improvement project. Diabetes
Care, 26(3), 750-757. https://doi.org/10.2337/diacare.26.3.750
Meltzer, S.J., Snyder, J., Penrod, J.R., Nudi, M., & Morin, L. (2010). Gestational diabetes
mellitus screening and diagnosis: a prospective randomised controlled trial comparing
costs of one-step and two-step methods. BJOG, 117(4), 407-415.
https://doi.org/10.1111/j.1471-0528.2009.02475.x
Mendelson, S., McNeese-Smith, D., Koniak-Griffin, D., Nyamathi, A., & Lu, M. C. (2008). A
community-based parish nurse intervention program for Mexican American women with

100

gestational diabetes. Journal of Obstetric, Gynecologic, and Neonatal Nursing,
37(4),415—425. https://doi.org/10.1111/j.1552-6909.2008.00262.x
Metzger, B.E. (2010). International Association of Diabetes and Pregnancy Study Groups
recommendations on diagnosis and classification of hyperglycemia in pregnancy.
Diabetes Care, 33(3), 676-682. https://doi.org/10.2337/dc09-1848
Metzger, B.E., Bybee, D.E., Freinke,l N., Phelps, R.L., Radvany, R.M., & Vaisrub, N. (1985).
Diabetes, 34, 111-115.
Metzger, B.E, Lowe, L.P, Dyer, A.R., Trimble, E.R., Chaovarindr, U., & Coustan, D.R. (2008).
Hyperglycemia and adverse pregnancy outcomes. HAPO Study Cooperative Research
Group. New England Journal of Medicine, 358, 1991–2002. doi:
10.1056/NEJMoa0707943
Meyers, L.S., Gamst, G., & Guarino, A.J. (2013). Applied multivariate research: Design and
interpretation. Los Angeles: Sage Publications.
Moore, T. (2016). Diabetes mellitus and pregnancy. Medscape. Retrieved from
http://emedicine.medscape.com/article/127547-overview
Moore, L.E., Clokey, D., Rappaport, V.J., & Curet, L.B. (2010). Metformin compared with
glyburide in gestational diabetes: a randomized controlled trial. Obstetrics and
Gynecology,115(1):55-9. https://doi.org/10.1097/AOG.0b013e3181c52132
Morrison,M., Lowe,J & Collins, C. (2014). Australian women’s experiences of living with
gestational diabetes.Women Birth, 27(1), 52-57. doi: 10.1016/j.wombi.2013.10.001
Moses, R. G., Barker, M., Winter, M., Petocz, P., & Brand-Miller,J. C. (2009). Can a low
glycemic index diet reduce the needfor insulin in gestational diabetes mellitus? A
randomized trial. Diabetes Care, 32(6), 996—1000. https://doi.org/10.2337/dc09-0007

101

Murphy, A., Guilar, A., & Donat, D. (2004). Nutrition education for women with newly
diagnosed gestational diabetes mellitus: Small-group vs. individual counselling.
Canadian Journal of Diabetes, 28(2), 147—151. Retrieved from
http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.118.8725&rep=rep1&type=pdf
Narasimhulu,D., Karakash,S., Weedon,J., & Minkoff, H. (2016). Patterns of internet use by
pregnant women, and reliability of pregnancy-related searches. Maternal and Child
Health Journal, 20(12), 2502-2509. https://doi.org/10.1007/s10995-016-2075-0
National Alliance for Health Information Technology. (2008). Defining key health
information technology terms. Retrieved from
https://www.nachc.com/client/Key%20HIT%20Terms%20Definitions%20Final_April_
08.pdf
National Learning Consortium. (2013). Using e-health tools to engage patients and caregivers.
Retrieved from www.healthit.gov
National Learning Corsortium. (2013). How to optimize patient portals for patient
engagementand meet meaningful use requirements. Retrieved from www.healthit.gov.
Nielsen, L.R., Ekbom, P., Damm, P., Glumer, C., Frandsen, M., Jensen, D., & Mathiesen, E.
(2004). HbA1c levels are significantly lower in early and

late pregnancy. Diabetes

Care,27,1200–1201. https://doi.org/10.2337/diacare.27.5.1200
Noel, H.C., Vogel, D.C., Erdos, J.J., Cornwall, D., & Levin, F. (2004). Home telehealth reduces
healthcare costs. Telemedicine Journal and e-Health, 10, 170-183.
https://doi.org/10.1089/tmj.2004.10.170

102

Nolan, J.A., McCrone, S., & Chertok, I.R. (2011). The maternal experience of having
diabetes in pregnancy. Journal of the American Academy of Nurse Practitioners,23,
611-618. https://doi.org/10.1111/j.1745-7599.2011.00646.x
Osborn, C.Y., Mayberry, L.S., Wallston, K.A. Johnson, K.B., & Elasy, T.A. (2013).
Understanding patient portal use: Implications for medication management. Journal of
Medical Internet Research, 15(7),e133. doi: 10.2196/jmir.2589.
Osborn, C.Y., Mayberry, L.S., Mulvaney, S.A., & Hess, R. (2010). Patient web portals to
improve diabetes outcomes: a systematic review. Current Diabetes Reports, 10(6), 422
435. https://doi.org/10.1007/s11892-010-0151-1
O’Sullivan J. In: Carbohydrate Metabolism in Pregnancy and the Newborn. Stowers J, Sutherland H, Eds,
editors. Edinburgh: Churchill Livingstone; 1984. Subsequent morbidity among gestational
diabetic women; pp. 174–180.

O’Sullivan, J.B., Charles, D., Mahan, C.M., & Dandrow, R.V. (1973). Gestational diabetes and
perinatal mortality rate. American Journal of Obstetrics and Gynecology,116, 901-905.
Parsons, J., Ismail, K., Amiel, S, & Forbes, A. (2014). Perceptions among women with
gestational diabetes. Qualitative Health Research, 24(4), 575-585.
https://doi.org/10.1177/1049732314524636
Pennic, F. (2012). Epic MyChart most widely used patient portal according to a KLAS survey.
HIT Consultant. http://hitconsultant.net/2012/12/07/epic-mychart-most-widely-used
patient-portal-according-to-klas-survey/
Pettitt, D.J., Knowler, W.C., Baird, H.R., and Bennett, P.H. (1987). Obesity on offspring of
diabetic Pima Indian women despite normal birthweight. Diabetes Care, 10, 76-80.

103

Plagemann, A., Harder, T., Kohlhoff, R., Rohde, W., & Dorner, G. (1997). Overweight and
obesity in infants of mothers with long-term insulin dependent diabetes or gestational
diabetes. International Journal of Obesity, 21, 451-456.
Po, Y.M. (2000). Telemedicine to improve patients’ self-efficacy in managing diabetes. Journal
of Telemedicine and Telecare, 6(5), 262-267.
Polit, D.F., & Beck, C.T. (2012). Nursing research: Generating and assessing evidence for
nursing practice. Philadelphia: Lippincott Williams and Wilkins.
Qiu, C., Enquobahrie, D.,Frederick, I. O., Abetew, D., & Williams, M. A. (2010). Glucose
intolerance and gestational diabetes risk in relation to sleep duration and snoring during
pregnancy: A pilot study. BMC Women’s Health, 10(17), 1-9.doi:10.1186/1472-6874-10
17
Quinn, C.C., Clough, S.S., Minor, J.M., Lender, D., Okafor, M.C., & Gruber-Baldini, A. (2008).
WellDoc mobile diabetes management randomized controlled trial: Change in clinical
and behavioral outcomes and patient and physician satisfaction. Diabetes Technology and
Therapeutics, 10, 160-168. https://doi.org/10.1089/dia.2008.0283
Reece, E.A. (2010). The fetal and maternal consequences of gestational diabetes mellitus. The
Journal of Maternal-Fetal and Neonatal Medicine, 23(3),199–203.
https://doi.org/10.3109/14767050903550659
Ricciardi, L., Mostashari, F., and Murphy, J., et al. (2013). A national action plan to support
consumer engagement via E-health. Health Affairs, 32(2), 376-384.
https://doi.org/10.1377/hlthaff.2012.1216
Rizzo, T.,Dooley, S., Metzger, B., Cho, N.,Ogata, E., & Silverman, B. (1995). Prenatal and
perinatal influences on long-term psychomotor development in offspring of diabetic
104

mothers. American Journal of Obstetrics and Gynecology,173(6), 1753-58.
http://dx.doi.org/10.1016/0002-9378(95)90422-0
Ronda, M.C.M., Dijkhorst-Oei, L.T., Rutten, G.E. (2015). Patients’ experiences with and
attitudes towards a diabetes patient web portal. PLoS One, 10(6), 1-11.
http://dx.doi.org/10.1371/journal.pone.0129403
Rowan, J.A., Hague, W.M., Gao, W., Battin, M.R., & Moore, M.P. (2008). MiG Trial
Investigators. Metformin versus insulin for the treatment of gestational diabetes. New
England Journal of Medicine,358, 2003-2015. doi: 10.1056/NEJMoa0707193
Ruggiero, L., Glasgow, J.M., Dryfoos, L, Rossi, J.S., Prochaska, J.O., Orleans, C.T…Johnson, S.
(1997). Diabetes self-management: Self-reported recommendations and patterns in a
large population. Diabetes Care, 20, 568-576.
Ryan, P. & Sawin, K.J. (2009). The Individual and Family Self-Management Theory:
Background and perspectives on context process and outcomes. Nursing Outlook, 57,
217-225.
Sahin, I. (2006). Detailed review of Rogers’ Diffusion of Innovations Theory and educational
technology-related studies based on Rogers’ theory. TOJET: The Turkish Online Journal
of Educational Technology,5(2), 1-14. Retrieved from
http://tojet.net/articles/v5i2/523.pdf
Sarkar U., Karter A.J., Liu, J.Y., Adler, N.E., Nguyen, R., & Lopez, A., et al. (2011). Social
disparities in internet patient portal use in diabetes: evidence that the digital divide
extends beyond access. Journal of American Medical Informatics Association,18: 318
321. https://doi.org/10.1136/jamia.2010.006015

105

Saudek, C.D., & Brick, J.C. (2009). The clinical use of hemoglobin A1c. Journal of Diabetes
Science and Technology, 3(4), 629-634.
https://dx.doi.org/10.1177%2F193229680900300402
Scaioli, G., Bert, F., Galis, V., Brusaferro, S., DeVito, E…Siliquini, R. (2015). Pregnancy and
internet: socioeconomic and geographic differences and e-health practices. Results from
an Italian multicenter study. Public Health, 129(9), 1258-1266.
http://dx.doi.org/10.1016/j.puhe.2015.06.012
Seckman, C. (2014). Electronic health records and applications for managing patient care. In R.
Nelson, & N. Staggers. (1st Eds.), Health informatics: An interprofessional approach (pp.
87-104). St. Louis: Elsevier.
Sermer, M., Naylor, C., Gare, D., Kenshole, A., Ritchie, J., Farine, D., Cohen, H…Chen, E.
(1995). Impact of increasing carbohydrate intolerance on maternal-fetal outcomes in
3637 women without gestational diabetes: The Toronto tri-hospital gestational diabetes
project. American Journal of Obstetrics and Gynecology,173(1), 146-156.
http://dx.doi.org/10.1016/0002-9378(95)90183-3
Shaw, R.J., & Ferranti, J. (2011). Patient-provider internet portals: Patient outcomes and use.
Computers, Informatics, Nursing, 29(12), 714-718.
https://doi.org/10.1097/NCN.0b013e318224b597
Shulman-Green, D., Jaser, S., Martin, F., Alonzo, A., Grey, M., McCorkle, R…Whittemore, R.,
(2012). Processes of self-management in chronic illness. Journal of Nursing
Scholarship,44(2), 136-144. https://doi.org/10.1111/j.1547-5069.2012.01444.x
Silverman, B.L., Metzger, B.E., Cho, N.H., and Loeb, C.A. (1995). Impaired glucose tolerance
in adolescent offspring of diabetic mothers. Diabetes Care, 18, 611-617.

106

Silvestre, A. Sue, V., & Allen, J.Y. (2009). If you build it, will they come? The Kaiser
Permanente model of online health care. Health Affairs, (28)2, 334-344.
https://doi.org/10.1377/hlthaff.28.2.334
Smith, K.E., Levine, B.A., Clement, S.C., Hu, M.J., Alaoui, A., & Mun, S.K. (2004). Impact of
MyCareTeam for poorly controlled diabetes mellitus. Diabetes Technology and
Therapeutics, 6, 828-835. https://doi.org/10.1089/dia.2004.6.828
Sorensen, L., Shaw, R., & Casey, E. (2009). Patient portals: Survey of nursing informaticists.
Studies in Health Technology and Informatics, 146, 160-165.
Unger, W. & Buehlow, J (2009). Hybrid concept analysis of self-management in adults newly
diagnosed with epilepsy. Epilepsy and behavior, 14(1), 89-95.
https://doi.org/10.1016/j.yebeh.2008.09.002
U.S. Preventative Taskforce (2015). Gestational diabetes mellitus screening. Retrieved from
https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStateme
ntFinal/gestational-diabetes-mellitus-screening
Vaidya, V. Partha,G. & Karmakar, M. (2012). Gender differences in utilizationof preventive care
services in the United States. Journal of Women’s Health,21(2), 140-145. doi:
10.1089/jwh.2011.2876
Vohr, B.R., & Boney, C.M. (2008). Gestational diabetes: The forerunner for the development of
maternal and childhood obesity and metabolic syndrome. Journal of Maternal-Fetal &
Neonatal Medicine, 21, 149-157.
Wald, J.S., Businger, A., Gandhi, T.K., Grant, R.W., Poon, E.G., Schnipper, J.L., Volk, L.A., &
Middleton, B. (2010). Implementing practice-linked pre-visit electronic journals in

107

primary care: Patient and physician use and satisfaction. Journal of American Medical
Informatics Association,16(5), 502-506. https://doi.org/10.1136/jamia.2009.001362
Weingart, S.N., Rind, D., Tofias, Z., & Sands, D.Z. (2006). Who uses the patient internet portal?
The PatientSite experience. Journal of the American Medical Informatics Association,
13(1), 91-95. https://dx.doi.org/10.1197%2Fjamia.M1833
Weitzman, E., Kaci, L., & Mandl, K. (2009). Acceptability of a personally controlled health
record in a community-based setting: Implications for policy and design. Journal of
Medical Internet Research, 11(2), e14. http://doi.org/10.2196/jmir.1187
Wright, A., Feblowitz, J., Samal, L., McCoy, A.B., & Sittig, D. F.(2014). The Medicare
Electronic Health Record Incentive Program: Provider performance on core and menu
measures. Health Services Research, 49, 325–46. doi: 10.1111/1475-6773.12134.
Yamin, C.K., Emani, S., Williams, D.H., Lipsitz, S.R., Karson, A.S., Wald, J.S., …Bates,D..
(2011). The Digital Divide in Adoption and Use of a Personal Health Record. Archives of
Internal Medicine, 171(6), 568–574. https://doi.org/10.1001/archinternmed.2011.34
Yogev Y, Xenakis EM, Langer O.(2004). The association between preeclampsia and the severity
of gestational diabetes: the impact of glycemic control. American Journal of Obstetrics
and Gynecology,191(5),1655-60. https://doi.org/10.1016/j.ajog.2004.03.074

108

Appendix A
Institutional Review Board Deferral, ProHealth Care

109

Appendix B
Insitutional Review Board Approval, Univeristy of Wisconsin-Milwaukee

110

CURRICULUM VITAE

Megan M. Anderson

EDUCATION

2013- present
University of Wisconsin-Milwaukee
 PhD- Nursing, anticipated May 2017
2000-2002
University of Illinois-Chicago
 Master’s Degree Nurse Midwifery
 Graduated with Honors, 4.0 GPA
1995-1999
University of Wisconsin-Madison



Bachelor of Science-Nursing
Graduated with Honors

HONORS/AWARDS
2016-2017
2013-2016
2000-2002
1999
1998-1999
1998-1999
1998
1997-1999

ProHealth Care nursing scholarship
Chancellor’s Award scholarship
Advanced Nurse Traineeship scholarship
Independent Study-Cuba
Honor’s Research Grant
Sigma Theta Tau
Independent Study-Europe
Honor’s Program

111

PROFESSIONAL EXPERIENCE
2014- Present






Director, Women & Children’s Services and Inpatient Behavioral
Health/Partial Program
ProHealth Care
Waukesha, WI
Oversees Women’s Health service line.
Strategic and operational oversight for 9 different specialty services both inpatient and
outpatient at 4 different locations with 251 reports.
Currently planning and developing a substance use in pregnancy program for women
and babies during pregnancy and post-delivery.
Engaged in the development of a maternity bundled payment program.
2010-2014






Manager, Women’s Center, ProHealth Care
Waukesha, WI

Oversaw operations and clinical work for urogynecology, perinatal, gyn oncology, and
women’s sexual health clinics at 3 locations.
Recruitment of staff and providers for all clinic locations.
Developed growth strategy for urogynecology and perinatal services. Also planned and
implemented a new sexual health program.
Ranked as a Tier 1 department in employee engagement survey, scoring 100% on each
of the following items: “the person I report to treats me with respect”,” the person I report to
encourages teamwork”, “ the person I report to is open to change”, “I respect the abilities of
the person to whom I report”, and “the person I report to is a good communicator.”
2003-2010

Perinatal Advanced Practice Nurse, Waukesha Memorial Hospital
Waukesha, WI

2001-2003

Registered Nurse, Birthing Center, Waukesha Memorial Hospital
Waukesha, WI

2000-2001

Registered Nurse, Alternative Birthing Center, Illinois Masonic
Medical Center, Chicago, IL

1999-2000

Registered Nurse, Birthing Center, Waukesha Memorial Hospital
Waukesha, WI

PROFESSIONAL COMMITTEES/INVOLVEMENT
2014
2013-2014
2011-2012
2009-2010
2008
2008-2010

Co-Chair of Women’s Health Service Line
Development of Women’s Health Service Line
Development of Women’s sexual health program
Pilot with GE data integration from Centricity Perinatal-Centricity Enterprise
Pilot with GE data integration from Centricity Perinatal-PeriData
Member, WHA CheckPoint Perinatal Indicators development workgroup
112

2007-2008
2003-2010
2007-2010
2007-2010
2005-2009
2005-2008
2005-2008
2003-2010
2003-2010
2000-2002
2001-2002
1998-1999
1998-1999
1998-1999

Pilot with GE data integration from Centricity EMR-Centricity Perinatal
Member, WAPC PeriData Committee
Community Advisory Board, National Children’s Study, Waukesha
Chair, ProHealth National Children’s Study Core Team
Chair, Perinatal Symposium Planning Committee, ProHealth Care
Member, Nursing Strategic Planning Committee, ProHealth Care
Co-Chair Nursing Strategic Initiative- SBAR rollout
Chair, Maternal/Newborn Transport Committee, ProHealth Care
Centricity Perinatal System Manager, Waukesha Memorial Hospital
Master’s research-Hispanic women and breast and cervical cancer, UIChicago
Advanced Nurse Traineeship, UI-Chicago
Student Representative on Faculty Recruitment Committee, UW-Madison
Honor’s Research Grant, UW-Madison
Co-President Student Nurse’s Association, UW-Madison

SERVICE/COMMUNITY INVOLVEMENT
2015-present
2013- present
2010- present
2008-2012

Volunteer for United Way campaign at ProHealth Care
Volunteer Lake Country Caring
Mentor for nurses and administrative staff
Nursing preceptor

PUBLICATIONS

Nelson, L., Doering, J.J, Anderson, M., & Kelly, L. (2012). Outcome of clinical nurse
specialist-led hyperbilrubinemia screening of late preterm newborns. Clinical Nurse
Specialist, 164-168. doi: 10.1097/NUR.0b013e3182506ad6
PROFESSIONAL ORGANIZATIONS
American Organization of Nurse Executives
Midwest Nursing Research Society
LICENSURE AND CERTIFICATIONS
Registered Nurse (RN) License- Wisconsin
Advanced Practice Nurse Prescriber (APNP) License- Wisconsin
Certified Nurse Midwife
AONE- Certified nurse manager and leader

113

